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Abstract
An adaptive treatment strategy (ATS) is an outcome-guided algorithm that allows personal-
ized treatment of complex diseases based on patients’ disease status and treatment history.
Conditions such as AIDS, depression, and cancer usually require several stages of treatment
due to the chronic, multifactorial nature of illness progression and management. Sequen-
tial multiple assignment randomized (SMAR) designs permit simultaneous inference about
multiple ATSs, where patients are sequentially randomized to treatments at different stages
depending upon response status. The purpose of the first part of the dissertation is to de-
velop a sample size formula to ensure adequate power for comparing two or more ATSs.
Based on a Wald-type statistic for comparing multiple ATSs with a continuous endpoint,
we develop a sample size formula and test it through simulation studies. We show via sim-
ulation that the proposed sample size formula maintains the nominal power. The proposed
sample size formula is applicable to designs with continuous endpoints and will be useful for
practitioners while designing SMAR trials to compare adaptive treatment strategies.
Hypothesis testing to compare adaptive treatment strategies are usually based on in-
verse weighting and g-estimation. However, regression methods that allow for comparison of
treatment strategies that flexibly adjusts for baseline covariates are not as straight-forward
using these methods due to the fact that one patient can belong to multiple strategies. This
poses a challenge for data analysts as it violates basic assumptions of regression modeling of
unique group membership. In the second part of the dissertation, we propose an “artificial
randomization” technique to make the data appear that each subject belongs to a specific
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ATS. This enables treatment strategy indicators to be inserted as covariates in a regression
model. The properties of this method are investigated analytically and through simulation.
Public Health Significance: Chronic diseases such as cancer and mental health problems
are becoming a major health care burden that present challenges to caregivers and pub-
lic health officials. Adaptive treatment strategies are a natural way of treating patients as
subjects’ conditions change repeatedly over a course of treatment. Finding optimal ATS is
therefore vital for the benefit of the patient as well as for society to reduce the health care
burden. SMAR (sequential multiple adaptive randomized) trials are convenient methods
to compare ATSs. In this dissertation, we provide a sample size formula to help design
SMARTs. We also introduce an “artificial randomization” technique that would allow re-
searchers to compare strategies in regression based models. These contributions enhance our
understanding of debilitating chronic diseases and will help managing them better.
Keywords: Sample size, power, sequential multiple assignment randomized trial, adaptive
treatment strategy, artificial randomization, multiple imputation, ANOVA.
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1.0 INTRODUCTION
In this chapter, we introduce a general review of important concepts and established facts
that will be referred to repeatedly throughout the dissertation.
1.1 SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIALS
AND ADAPTIVE TREATMENT STRATEGIES
An adaptive treatment strategy (ATS) is an outcome-guided algorithm that allows personal-
ized treatment [14, 20, 23] of complex diseases based on disease status (response, recurrence,
remission, relapse) and intermediate treatment history. ATSs are also called dynamic treat-
ment regimes (DTR) due to time-varying nature of the approach [27, 29]. Complex diseases
such as AIDS, depression, and cancer usually involve several stages of treatment due to
dynamic disease progression. For instance, a patient with depression may benefit if she ini-
tiates treatment with citalopram (CIT). Depending on response, she may remain on CIT
or switch to or add another medication or psychosocial treatment during the next phase
of treatment. An example of an adaptive treatment strategy from a SMART design of a
depression trial (STAR*D) (Rush et al., 2004) [33] is, “Treat with CIT for 6-8 weeks; if
response is not achieved with CIT; augment with cognitive behavioral therapy (CBT) for 8
weeks; otherwise, continue with CIT for another 8 weeks”. Given first stage, Aj, j = 1, 2
and second stage treatments, Bk, k = 1, 2 and Cl, l = 1, 2, one can define ATS as AjBkCl to
indicate “Treat with Aj followed by Bk, if response and Cl, if no response”. Learning about
ATSs can be realized by studying sequences of treatments in a whole trial.
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Sequential multiple assignment randomized trials (SMARTs) are multistage trials whereby
subjects are sequentially randomized and re-randomized to available treatment options in
several stages after enrollment. Randomization of treatments at each stage is dependent on
covariate history (such as patient preference) and previous treatment response. Although
previous studies have described SMARTs [12, 13], their characterization was formalized by
Murphy (2005) [22]. SMARTs allow us to collect data which in turn inform the development
of adaptive treatment strategies (ATSs) to guide treatment of future patients. In practice,
SMAR designs usually contain two to three stages of treatment.
1.2 WALD TEST AND POWER
A Wald-test based approach for power and sample size computation is useful in a hypothesis
testing setting in statistics (Wald, 1943) [41]. Wald (1943) developed the theory for testing
multiple parameters when the number of observations is large. From large sample theory,
if appropriate assumptions hold, it is established that the maximum likelihood estimator
(MLE) Θˆ of a vector of parameters Θ, has a limiting normal distribution, that is
√
n
(
Θˆ−Θ
)
d−→ N (0, I−1 (Θ))
as n → ∞, where d−→ is convergence in distribution and I (Θ) is the information matrix.
Because I (Θ) is continuous in Θ, then for a sequence of estimators Θˆn,
I
(
Θˆn
)
p−→ I (Θ)
as n →∞, where p−→ is convergence in probability. By Slutsky’s theorem,
n
(
Θˆn −Θ
)T
I
(
Θˆn
)(
Θˆn −Θ
)
d−→ V T I (Θ)V
where r = dim (Θ), V ∼ Nr (0, I−1 (Θ)) and V T I (Θ)V ∼ χ2r,α. To determine the significance
of a test, Wald-test statistic is compared with its theoretical frequency distribution, which is
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the chi-square distribution with r degrees of freedom under the null-hypothesis (χ2r). That
is, the Wald test rejects H0 : Θ = Θ0 in favor of H1 : Θ 6= Θ0 where
Wn (Θ0) = n
(
Θˆn −Θ0
)T
I (Θ0)
(
Θˆn −Θ0
)
≥ χ2r,α
has asymptotic level α. Usually, I (Θ0) is evaluated by replacing the MLE Θˆn into the
Hessian matrix.
We develop a sample size formula based on Wald-type statistic to compare multiple
ATSs with a continuous endpoint. The sample size required to test the null hypothesis with
specified significance level α and power 1− β against the alternative is computed by finding
the non-centrality parameter λ from a non-central chi-square distribution with r degrees of
freedom and then equating it with nΘTCT [CΣCT ]−1CΘ where C is a contrast matrix and
Σ is the variance-covariance matrix of Θ.
1.3 INVERSE PROBABILITY WEIGHTING
In clinical and biomedical research, missing data is an unavoidable phenomenon. Naive es-
timation procedures that only consider fully observed data induce bias. Therefore, weighted
estimation procedures are suggested. Inverse probability weighting (IPW) for estimating
population means in survey sample non-response problems was first described by Horvitz
and Thompson (1952) [9]. One such method, namely, the Horvitz-Thompson mean estimator
can be written as µˆHT = 1
N
∑N
i=1
yi
pii
, where yi, i = 1, ..., n are independent measurements from
n ≥ N strata with common population mean µ; pii is the probability that a randomly selected
subject belongs to stratum i. A subject weighted by 1
pii
represents himself/herself as well
as missing subjects 1
pii
− 1 in the same stratum. Horvitz-Thompson’s mean estimator gives
more weight to subjects with more missingness in their strata. A slight variant of Thomp-
son’s estimator is the normalized inverse probability weighted estimator, µˆIPWN =
∑N
i=1
Riyi
pii∑N
i=1
Ri
pii
,
where Ri = 1 if yi is observed and Ri = 0 if yi is missing. Weighting boosts the sample size
by expanding the representation of observed data. Applications of IPW has been adequately
covered in articles by Robins et al. [28], Murphy et al. [21] and Bembom and van der
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Laan [2]. In sequential randomized trials, not everyone in the study follows one of the eight
regimes, say AjBkCl, j, k, l = 1, 2. Assume a population follows regime A1B1C1. Because
the estimated strategy mean is biased, inversely weighting responders who were assigned to
B1 and non-responders who were assigned to C1 by their corresponding probabilities of ran-
domization would correct the bias. Weighting adjusts the mean by creating representation
of missing responders (B2) and non-responders (C2).
1.4 LEUKEMIA STUDY
Cancer and Leukemia Group B (CALGB) clinical trial (Protocol 8923) was designed for
treatment of acute myelogenous leukaemia (AML) among elderly patients of 60 years and
older [36]. It was a double-blind, placebo-controlled two-stage trial with two randomiza-
tions conducted in the early 1990’s. At the first stage, patients were initially randomized
to two induction therapies granulocyte-macrophage colony-stimulating factor (GM-CSF) or
placebo, following a standard chemotherapy. Response is defined as “complete remission”
where complete remission is defined as recovery of morphologically normal bone marrow and
blood counts (i.e., neutrophils = 1,500/µl and platelets < 100,000/µl), and no circulating
leukemic blasts or evidence of extramedullary leukemia. In the second stage, responders were
randomized to two maintenance therapies, namely, intensification therapy I (cytarabine) and
intensification therapy II (cytarabine + mitoxantrone). For simplicity we will use the no-
tations, the first stage treatments, A1: standard chemotherapy + placebo, A2: standard
chemotherapy + GM-CSF; the second stage treatments are: B1, B2: intensification treat-
ments I and II. By design, this trial offers second stage randomization to stage 1 treatment
responders but not to non-responders. Figure 1 is a schematic of CALGB 8923 study. We
use the data from this study to compare the treatment strategies in a regression setting and
further generate informative strategies for leukemia treatment.
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AML 
A1 
A2 
Responder 
Non-
Responder 
Non-
Responder 
Responder 
A1 
A2 
Chemo + 
Placebo 
Intensification I 
Intensification II 
Intensification I 
Intensification II 
Chemo + GF-
CSF 
B2 
B2 
B1 
B1 
Follow up 
Follow up 
Patients with AML are randomized to initial treatments A1 and A2. If a patient responds
to the initial treatment he/she is randomized to either B1 or B2, otherwise the patient goes
to follow up.
Figure 1: CALGB 8923 Study.
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1.5 MOTIVATION AND OBJECTIVES
SMAR designs are becoming popular in the context of long term treatment options for
chronic diseases. The appeal lies in their naturalistic approach as patient characteristics
dictate treatments. Same treatments given to heterogeneous individuals might not have the
same effectiveness since, naturally, response is subject-specific (Nahum-Shani et al., 2012)
[24]. SMAR trials allow patients to be randomized in multiple stages. Critical decisions
are made at each stage of SMAR design when clinically significant event happens during
the course of treatment. That is, when patients respond well to sequences of treatments or
otherwise.
ATSs are tools that operationalize critical decisions that physicians utilize to manage
these complex diseases. ATSs take inputs such as patient characteristics, covariate history,
previous treatments and output a treatment choice. Construction of ATSs is made possi-
ble via data collected from sequential multiple assignment randomized trials (SMARTs) or
observational studies.
The objective of this dissertation is twofold. First, we propose sample size formulas for
various SMAR designs when the outcome of interest is continuous. Sample sizes have been
developed for survival and continuous outcomes to compare strategies [6, 7, 16]. However,
Wallace and Moodie (2014) [42] suggest limiting the number of strategies because of the
dangers of creating high dimensional problem and impracticable sample sizes. As such, we
also propose a sample size formula for pairwise comparisons that target only desired number
of ATSs. Second, we propose the simple multiple artificial randomization tool (SMART)
estimator that combines ‘artificially randomized’ estimators borrowing techniques from mul-
tiple imputation methods of Rubin (1977, 1987) [31, 32]. Subsequently, we show how the
artificial randomization approach can be used to construct regression models to compare
strategies adjusting for baseline covariates, and hence inform further useful strategies.
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2.0 DESIGN OF SEQUENTIALLY RANDOMIZED TRIALS FOR
TESTING ADAPTIVE TREATMENT STRATEGIES
2.1 INTRODUCTION
An adaptive treatment strategy (ATS) is an outcome-guided algorithm that allows personal-
ized treatment [14, 20, 23] of complex diseases based on disease status (response, recurrence,
remission, relapse) and intermediate treatment history. ATS is also called dynamic treat-
ment regimes (DTR) due to time-varying nature of the approach [27, 29]. Complex diseases
such as AIDS, depression, and cancer usually involve several stages of treatment due to dy-
namic disease progression. For instance, a patient with depression may benefit if she initiates
treatment with citalopram (CIT). Depending on response, she may remain on CIT or switch
to or add another medication or psychosocial treatment during the next phase of treatment
[33]. In principle, a clinician monitors a depressed patient and decides on interventions at
different time points based on the patient’s clinical status. Availability of multiple treatment
options at each stage of treatment, various possibilities for the duration of each stage, and
various responses that can be achieved through different stages of therapy could lead to a
multitude of adaptive treatment strategies. Examples of treatment strategies for a patient
with moderate depression include [33]:
1. Treat with CIT for 6-8 weeks; if response is not achieved with CIT, augment with cog-
nitive behavioral therapy (CBT) for 8 weeks, otherwise continue with CIT for another 8
weeks.
2. Treat with CIT for 6-8 weeks; if response is not achieved with CIT, switch to CBT for 8
weeks, otherwise switch to BUS (buspirone) for another 8 weeks.
7
3. Treat with CIT for 6-8 weeks; if response is not achieved with CIT, switch to CBT for 8
weeks, otherwise switch to BUP-SR (bupropion sustained release) for another 8 weeks.
4. Treat with CIT for 6-8 weeks; if response is not achieved with CIT, switch to SERT
(sertraline) for 8 weeks, otherwise switch to CBT for another 8 weeks.
Adaptive treatment strategies are often compared via sequential multiple assignment
randomized (SMAR) designs [12, 13, 22]. Even though SMAR trials are useful for comparing
ATSs because different ATSs can be tested from the same experimental design and the
procedure for inference about ATSs from data arising from such trials are well-established,
the design issues (e.g. sample size and power) have not been adequately addressed. This
may be due to the challenges posed by the adaptive and sequential nature of SMAR designs.
Nevertheless, a few articles have alluded to the development of sample size formula for SMAR
designs.
Murphy [22] provides a sample size formula to test the equality of two strategies that do
not share same initial sets of treatments, making data from two groups of patients following
these strategies statistically independent. Feng and Wahed [6] also constructed a sample size
formula for survival outcomes. However, their formula was developed for censored survival
times to test equality of point-wise survival probabilities under two ATSs that have the
same initial, but different second stage treatments. They also proposed another formula
based on weighted log-rank test for the equality of survival curves under two strategies that
share different initial treatments [7]. Recently, Li and Murphy [16] presented a sample size
formula for survival data to relax the assumptions set forth by Feng and Wahed [6, 7].
Oetting et al. [25] established four sample size formulas, of which only two are relevant to
adaptive treatment strategies. One of the formulas (referred to as #3 in their chapter) deals
with a hypothesis testing the equality of a pair of strategy means. The other relevant formula
(referred to as #4 in their chapter) is developed with the goal of finding the best strategy (as
opposed to hypothesis testing comparing multiple strategies). Dawson and Lavori [3] also
devised a sample size formula for the nested structure of successive SMAR randomizations
when the outcome is continuous. They extended the sample size for the usual t-test to
be applicable to SMAR trials. Using a semi-parametric approach, their formula includes
stage-specific variance inflation factor (VIF) and marginal outcome variance σ2Y . Due to the
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presence of between-strategy covariance, one cannot make inference for a pair of strategy
means that share the same initial treatments by just pooling the VIF’s and marginal outcome
variances across the stages. As a remedy, Dawson and Lavori [4] proposed a conservative
approach to adjust the sample size formula using the VIF. The caveat with their approach is
its difficulty of application. It involves cumbersome computation of all stage-specific VIFs,
σ2Y and coefficient of determination by regressing the final outcome on previous states. More
recent simulation work by Ko and Wahed [11] considered the power for detecting differences
between multiple strategy means for arbitrary sample sizes for a two-stage SMAR design.
Most of the work related to sample sizes in SMAR trials are either confined to two-
strategy comparisons [12, 7] or require assumptions about population parameters that are
difficult to ascertain (e.g. VIF’s and stage-specific variances) in multi-strategy comparison
settings. We derive sample size formulas for a variety of SMAR designs in order to test
specific alternative hypotheses related to continuous outcomes.
The rest of this chapter is organized as follows. In Section 2.2, we introduce notation
and consider three SMAR designs that are being used in various disease areas. The param-
eters needed to be specified in advance correspond to well-defined subgroups in the patient
population and hence are relatively simple to specify. In Section 2.3, we show estimation of
strategy means and their corresponding variances and covariances given some fundamental
assumptions. Based on a Wald-type statistic, in Section 2.4 we derive an overall sample
size formula required to compare multiple strategy means. In Section 2.5, we introduce a
t-test based sample size formula to power pairwise comparisons among all or selected ATSs.
In Section 2.6, we validate our sample size formulas through simulation experiments. We
conclude the chapter with a discussion in Section 2.7.
2.2 SET-UP
We consider three two-stage SMAR designs. Figures 2, 3 and 4 display the three SMAR
designs. In the first design, n subjects are to be randomized to two induction treatments
Aj, j = 1, 2. Then maintenance treatments, Bk, k = 1, 2, are to be administered randomly
9
if they responded to induction treatments, or else they are randomized to Cl, l = 1, 2.
We use the Lei et al. [14] design for alcohol-dependence interventions as an example to
explain the first design (Figure 1). All patients are provided with “NTX+MM” as their
initial intervention (NTX = naltrexone, MM = medical management). Then patients are
randomized to two groups based on how the intermediate response to “NTX+MM” would
be ascertained. In one group, referred to as A1, the response criteria would be stringent
(2+ days of heavy drinking), whereas in the other group, referred here forth as A2, the
criterion would be lenient (5+ days of heavy drinking). Following eight weeks of treatment,
participants are randomized to the second line treatments depending on their non-response
status. Non-responders were re-randomized to either “NTX” (B1) or “NTX+TDM” (B2),
otherwise, they were re-randomized to two maintenance treatments: “CBI+MM+Placebo”
(C1) or “CBI+MM+NTX” (C2), where CBI = combined behavioral intervention, and TDM
= telephone disease management. At the end of the study, the primary outcome (defined as
“percent of heavy drinking days” over the last two months of the study) was obtained.
Design 1 allows inference related to eight possible ATSs, namely AjBkCl, j, k, l = 1, 2,
where AjBkCl stands for “Treat with Aj followed by Bk if they respond, or by Cl if not”.
For example, one might want to test the equality of all strategy means H0 : µ111 = µ112 =
µ121 = µ122 = µ211 = µ212 = µ221 = µ222, where µijk is the mean response under strategy
AjBkCl, j, k, l = 1, 2 against the alternative of at least one pair being different. Testing
equality of any combination of treatment strategies (e.g. pairwise comparisons) may also be
of interest. In the sequel we consider the sample sizes required to test varieties of treatment
strategy comparisons with adequate statistical power.
The second design was used by Pelham et al. [26] for an Attention Deficit Hyperactivity
Disorder (ADHD) clinical trial (Figure 3). This trial involved treating children with ADHD
with behavioral and pharmacological interventions during stage 1. In the first stage partic-
ipants were randomized to low intensity “psychostimulant drug (low intensity MED)” (A1)
or low intensity “behavioral modification (low intensity BMOD)” (A2). Behavioral modifi-
cation consists of school-based, weekend and at-home activity sessions. A child’s response
to the first line treatment is assessed using Impairment Rating Scale (IRS) and an individ-
ualized list of target behaviors (ITB). IRS is a comprehensive measure of improvement in
10
Randomize 
A1 
A2 
Non-
Responder 
Responder 
Responder 
Non-
Responder 
C1 
B1 
C2 
B1 
C1 
C2 
NTX+MM+ 
Stringent 
CBI+MM+Placebo 
CBI+MM+NTX 
CBI+MM+Placebo 
CBI+MM+NTX 
NTX+MM+ 
Lenient 
 
B2 
NTX+Phone 
NTX 
B2 
NTX 
NTX+Phone 
At entry, patients are randomized to initial treatments A1 and A2. If a patient responds to the
initial treatment she is randomized to either B1 or B2, otherwise the patient is randomized
to either C1 or C2.
Figure 2: Design 1.
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Randomize 
A1 
A2 
Non-
Responder 
Responder 
Responder 
Non-
Responder 
A1 
A2 
Low intensity 
BMOD 
Continue Low 
Intensity BMOD 
Continue Low 
Intensity MED 
Augment MED 
Intensify BMOD 
Augment BMOD 
Intensify MED 
Low intensity 
MED 
B2 
B2 
B1 
B1 
At entry, patients are randomized to initial treatments A1 and A2. If a patient responds
to the initial treatment she stays on the same initial treatment, otherwise the patient is
re-randomized to subsequent treatments: B1 or B2 if she does not respond to A1; similarly,
to B1 or B2 if she does not respond to A2.
Figure 3: Design 2.
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social performance while ITB is a child-specific monitor of social performance. IRS and ITB
are “tailoring” variables that determine response status and randomization to the second
stage treatments. A response is defined if the child attains an average ITB performance of
less than 75% and is reported impaired by teachers on at least one domain in IRS. Based
on these tailoring variables, participants who responded to first-stage treatment remained
on the same treatment whereas non-responders were re-randomized. Children who did not
respond to low intensity BMOD (A1) were re-randomized to either intensified BMOD (A1)
or BMOD augmented with MED (B2). Those children who did not respond to low intensity
MED (A2) were re-randomized to either intensified MED (B1) or MED augmented with
BMOD (B2).
Thus, if a patient responds to A1 then she stays on A1 but is randomized to B1 or B2 for
non-response. Similarly, if a patient responds to A2 then she stays on A2; otherwise, she is
switched to either B1 or B2. Following the notation from the first design, there are 4 possible
treatment strategies, namely, A1A1B1, A1A1B2, A2A2B1, or A2A2B2. Note that it might
seem redundant to use two A1’s or A2’s to define the strategies, but this formulation allows
us to cast the problem in the frame of Design 1. It might be of interest to test equality of
all 4 strategy means, H0 : µ111 = µ112 = µ221 = µ222.
The third design considered is described in Thall et al. [39] (Figure 4). Patients received
one of three initial treatments A1, A2 and A3 during the first randomization. If a patient
initially assigned to A1 responded, she would remain on A1 during the second stage; otherwise
she would be randomized to A2 or A3. Similarly, if a patient responds to initial treatment
A2 then he/she would continue A2 in the second stage; otherwise would be randomized to
A1 or A3. Similarly, patients not responding to A3 would be re-randomized to A1 or A2 in
the second stage. There are 6 possible regimes, namely, A1A1A2, A1A1A3, A2A2A1, A2A2A3,
A3A3A1, or A3A3A2. The null hypothesis of equality of strategy means is, H0 : µ112 = µ113 =
µ221 = µ223 = µ331 = µ332. For all the three designs, we develop a sample size formula to
detect meaningful differences between strategy means.
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Randomize 
A1 
A3 
Non-
Responder 
Responder 
Responder 
Non-
Responder 
A2 
A1 
A3 
A3 
A1 
A2 
A2 
Responder 
Non-
Responder 
A2 
A1 
A3 
At entry, patients are randomized to initial treatments A1, A2 and A3. If a patient responds
to the initial treatment she stays on the same initial treatment, otherwise the patient is
re-randomized to subsequent treatments: A2 or A3 if she does not respond to A1; A1 or A3
if she does not respond to A2; A1 or A2 if she does not respond to A3.
Figure 4: Design 3.
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2.3 COMPARING MULTIPLE TREATMENT STRATEGIES
The goal is to design a sample size formula for a test that detects differences in strategy
means from SMAR designs with a continuous endpoint. The formula is based on Design
1 (Figure 2) which is described in Section 2.2. In order to achieve this goal, let us introduce
the following notation. Let Rj be the counterfactual response indicator for an individual who
responded to Aj, j = 1, 2; Y (AjBk) is the counterfactual outcome of an individual had he/she
received Aj, responded, then took Bk; similarly, Y (AjCl) is the counterfactual outcome of
an individual had he/she received Aj, did not respond, then took Cl. Based on these three
counterfactual outcomes, consider Y (AjBkCl) as the outcome under strategy AjBkCl, which
can be written as
Y (AjBkCl) = RjY (AjBk) + (1−Rj)Y (AjCl), j, k, l = 1, 2. (2.1)
To clarify the distinction between the observed and unobserved quantities, for example, for
a patient who received A1, responded, and received B1, {R2, Y (A1B2), Y (A2B1), Y (A2B2)}
are all unobservable. What is observed here is only Y (A1B1) (see consistency assumption
below). As described in Section 2, we are interested in estimating µjkl = E{Y (AjBkCl)}.
Conditioning on Rj, µjkl can be expressed as
µjkl = pijµAjBk + (1− pij)µAjCl , (2.2)
where µAjBk = E{Y (AjBk)} is the sub-group mean of the population receiving Aj followed
by Bk, µAjCl = E{Y (AjCl)} is sub-group mean of the population receiving Aj followed by
Cl. Our development of the sample size formula is based on Wald-type test statistic. Thus,
an estimator of the strategy means and corresponding variance and covariance expressions
is required. We will rely on the method of normalized inverse probability weighting (IPWN,
Ko and Wahed, 2012) to construct unbiased estimator of strategy means. Although we focus
on sample size for a continuous endpoint, the formulas developed apply equally for designs
with a binary endpoint.
Consider Design 1 (Figure 2) in Section 2.2. Contrary to the counterfactual variables
defined above, the observed data for this design consists of i.i.d (independent and identically
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distributed) random variables, (Xji, RiZki, (1 − Ri)Z ′li, Yi) where Xji = 1, if the ith patient
is randomized to Aj; 0 otherwise. Yi is the observed outcome for the i
th individual, Ri is
the indicator for initial response, Ri = 1 if the i
th patient responded to initial therapy, 0,
otherwise; Zki is the indicator for receiving Bk, i.e. Zki = 1 if subject i is randomized to
receive Bk after responding to the first-stage treatment, 0, otherwise; similarly, Z
′
li is the
indicator for receiving Cl. We make the usual assumptions of causal inference to construct
consistent estimators for µjkl [29]. They are:
A1. Consistency Assumption: A patient’s counterfactual outcome under the observed inter-
vention (exposure) and the observed outcome agree. In the SMAR trial considered here,
Ri = X1iR1i + (1−X1i)R2i, (2.3)
and
Yi = X1i [R1iYi(A1B1) + (1−R1i)Yi(A1C1)]+(1−X1i) [R2iYi(A2B1) + (1−R2i)Yi(A2C2)] ,
(2.4)
where R1i and R2i are indicators for counterfactual response to A1 and A2, respectively,
defined previously. The consistency assumption (CA) allows us to connect counterfactual
and observed data.
A2. Sequential Randomization Assumption: The probability of a particular treatment allo-
cation at stage a at a treatment time k does not depend on the counterfactual outcome
given observed data up to but not including stage k randomization. This assumption
follows since treatments are assigned randomly at each stage.
A3. Positivity: There is a non-zero probability of receiving any level of intervention for every
combination of values of interventions.
Under these assumptions, we define the normalized weighted inverse probability estimator
for strategy mean µjkl is given by
µˆIPWNjkl =
∑n
i=1WjkliYi∑n
i=1Wjkli
, (2.5)
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where Wjkli = Xji
{
RiZki
Pk
+
(1−Ri)Z′li
Ql
}
, Xji is the assignment indicator for first-stage treat-
ment Aj; Pk and Ql are probabilities of second treatment assignment for responders and
non-responders.
Estimator (2.5) is similar to that in Ko and Wahed (2012) (Section 3.3) except that it
treats the group sample sizes in Stage 1 as random rather than being treated as fixed. This is
more reasonable because the group sizes in Stage 1 are determined through randomization.
The IPWN estimator, µˆIPWNjkl , defined in Equation (2.5) is consistent and asymptotically
normal. This can be shown as follows. We can write,
√
n(µˆIPWNjkl − µjkl) =
√
n
[∑n
i=1WjkliYi∑n
i=1Wjkli
− µjkl
]
= n−1/2
∑n
i=1 Wjkli(Yi − µjkl)
1
n
∑n
i=1 Wjkli
.
By the weak law of large numbers, 1
n
∑n
i=1Wjkli
p−→ 1
κj
where κj is the inverse of the random-
ization probability to Aj (i.e., κj =
1
P (Xji=1)
). This follows from the fact that Wjkli’s are i.i.d
random variables with expectation,
E{Wjkli} = E
[
E
{
RiZki
Pk
+
(1−Ri)Z ′li
Ql
}
Xji|Xji, Ri
]
= E
[
XjiE
{
RiZki
Pk
+
(1−Ri)Z ′li
Ql
}
|Ri
]
= E [XjiE{Ri + (1−Ri)}|Ri]
= E [Xji]
= P (Xji = 1)
=
1
κj
.
Also, by the central limit theorem, n−1/2
∑n
i=1Wjkli(Yi − µjkl) d−→ N(0, σ2jkl), where σ2jkl
is given in Equation (2.7) below. Therefore, by Slutsky’s theorem,
√
n(µˆIPWNjkl − µjkl) is
asymptotically equivalent in distribution to n−1/2κj
∑n
i=1Wjkli(Yi − µjkl) which is normally
distributed as N(0, σ2jkl), where σ
2
jkl is defined below. It can also be shown that,
√
n(µˆIPWNjkl − µjkl) = n−1/2
n∑
i=1
ψjkli + op(1), (2.6)
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where ψjkli = κjWjkli(Yi − µjkl) is the influence function of the estimator µˆIPWNjkl and
op(1) is a term that converges to zero in probability. Therefore, the asymptotic variance
of
√
n(µˆIPWNjkl − µjkl) is given by,
σ2jkl = κj
[
pij
Pk
{σ2AjBk + (1− pij)2(µAjBk − µAjCl)2}+
1− pij
Ql
{σ2AjCl + pi2j (µAjBk − µAjCl)2}
]
,
(2.7)
where pij is the response rate for first stage treatment Aj; σ
2
AjBk
and σ2AjCl are variances of
the outcome in the population of patients who received the sequence of treatments AjBk
and AjCl, respectively; µAjBk and µAjCl are defined as before.
Following Ko and Wahed (2012), the variance formula in Equation (2.7) is derived as
follows, σ2jkl = var(ψjkli) = var(κjWjkli(Yi − µjkl)) = κ2jE [Wjkli(Yi − µjkl)]2. This variance
can be expressed in terms of subgroup-specific population parameters. For example, consider
µˆIPWN111 . In this case, the weight is defined as W111i = X1i
{
RiZ1i
P1
+
(1−Ri)Z(
′)
1i
Q1
}
, and therefore,
W 2111i = X1i
{
RiZ1i
P 21
+
(1−Ri)Z′1i
Q21
}
. Then,
E
[
κ21W
2
111i(Yi − µ111)2
]
= κ21E
[
X1i
{
RiZ1i
P 21
+
(1−Ri)Z ′1i
Q21
}
(Yi − µ111)2
]
(2.8)
.
Under assumptions (A1)-(A3), using a series of conditional expectations, we can show
that
E
[
κ21W
2
111i(Yi − µ111)2
]
= κ1
[
pi1
P1
{
σ2A1B1 + (µ111 − µA1B1)2
}
+
(1− pi1)
Q1
{
σ2A1C1 + (µ111 − µA1C1)2
}]
.
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= κ
2
1E
X1i
RiZ1iP21 +
(1− Ri)Z
′
1i
Q21
 (Yi − µ111)2

= κ
2
1EE
[
X1i
{
RiZ1i
P21
}
{RiYi(A1B1) + (1− Ri)Yi(A1C1)− µ111}2 |Ri, X1i, Yi(A1B1), Yi(A1C1)
]
+
κ
2
1EE
X1i
 (1− Ri)Z
′
1i
Q21
 {RiYi(A1B1) + (1− Ri)Yi(A1C1)− µ111}2 |Ri, X1i, Yi(A1B1), Yi(A1C1)

= κ
2
1E [Z1i|Ri, X1i, Yi(A1B1)]EE
[
X1i
{
Ri
P21
}
{RiYi(A1B1) + (1− Ri)Yi(A1C1)− µ111}2 |Ri, X1i, Yi(A1B1), Yi(A1C1)
]
+
κ
2
1E
[
Z
′
1i|Ri, X1i, Yi(A1C1)
]
EE
[
X1i
{
(1− Ri)
Q21
}
{RiYi(A1B1) + (1− Ri)Yi(A1C1)− µ111}2 |Ri, X1i, Yi(A1C1)
]
= κ
2
1E [Z1i|Ri, X1i, Yi(A1B1)]E
[
X1i
P21
E
[
RiY
2
i (A1B1)− 2µ111 {RiYi(A1B1) + (1− Ri)Yi(A1C1)} + µ2111|Ri, X1i
]]
+
κ
2
1E
[
Z
′
1i|Ri, X1i, Yi(A1C1)
]
E
[
X1i
Q21
E
[
(1− Ri)Y 2i (A1C1)− 2µ111 {RiYi(A1B1) + (1− Ri)Yi(A1C1)} + µ2111|Ri, X1i
]]
= κ
2
1P1E
[
X1i
P21
E
[
RiY
2
i (A1B1)− 2µ111 {RiYi(A1B1)} + µ2111|Ri, X1i
]]
+
κ
2
1Q1E
[
X1i
Q21
E
[
(1− Ri)Y 2i (A1C1)− 2µ111 {(1− Ri)Yi(A1C1)} + µ2111|Ri, X1i
]]
= κ
2
1P1E
[
X1i
P21
E
[
Ri(σ
2
A1B1
+ µ
2
A1B1
)− 2µ111RiµA1B1 + µ
2
111|Ri, X1i
]]
+
κ
2
1Q1E
[
X1i
Q21
E
[
(1− Ri)(σ2A1C1 + µ
2
A1C1
)− 2µ111(1− Ri)µA1C1 + µ
2
111|Ri, X1i
]]
= κ
2
1E
[
X1iE
[
Ri
P1
{
σ
2
A1B1
+ µ
2
A1B1
− 2µA1B1µ111 + µ
2
111
}
+
(1− Ri)
Q1
{
σ
2
A1C1
+ µ
2
A1C1
− 2µA1C1µ111 + µ
2
111
}
|X1i
]]
= κ
2
1E
[
X1i
[
pi1
P1
{
σ
2
A1B1
+ (µ111 − µA1B1 )
2
}
+
(1− pi1)
Q1
{
σ
2
A1C1
+ (µ111 − µA1C1 )
2
}]]
= κ1
[
pi1
P1
{
σ
2
A1B1
+ (µ111 − µA1B1 )
2
}
+
(1− pi1)
Q1
{
σ
2
A1C1
+ (µ111 − µA1C1 )
2
}]
.
Consequently, the asymptotic variance of µˆ111 is given by,
var(µˆIPWN111 ) =
κ1
n
[
pi1
P1
{
σ2A1B1 + (µ111 − µA1B1)2
}
+
(1− pi1)
Q1
{
σ2A1C1 + (µ111 − µA1C1)2
}]
=
σ2111
n
.
Estimators that share the same first-stage treatment are correlated as they use a common
group of observations. Consider µˆIPWN111 and µˆ
IPWN
112 . To derive the covariance between strat-
egy means µˆIPWN111 and µˆ
IPWN
112 , we note that similar to
√
n(µˆIPWN111 −µ111),
√
n(µˆIPWN112 −µ112)
is distributionally equivalent to n−1/2κ1
∑n
i=1 W112i(Yi−µ112). Therefore, the asymptotic co-
variance of
√
n(µˆIPWN111 − µ111) and
√
n(µˆIPWN112 − µ112) is given by,
σ111,112 = cov(ψ111i, ψ112i) = cov(κ1W111i(Yi − µ111), κ1W112i(Yi − µ112))
= E
[
κ21W111iW112i(Yi − µ111)(Yi − µ112)
]
.
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Since W111iW112i =
RiZ1iX1i
P 21
, we can further simplify the above as,
σ111,112 = E
[
κ21
RiZ1i
P 21
X1i(Yi − µ111)(Yi − µ112)
]
By the Consistency Assumption,
= E
{
E
[
κ21
RiZ1i
P 21
X1i(Yi(A1B1)− µ111)(Yi(A1B1)− µ112)|Ri, X1i, Yi(A1B1)
]}
= κ21E
[
X1iE
[
Ri
P 21
(Yi(A1B1)− µ111)(Yi(A1B1)− µ112)
]
E{Z1i|Ri, X1i, Yi(A1B1)}
]
= κ21EE
[
X1i
Ri
P1
(Yi(A1B1)− µ111)(Yi(A1B1)− µ112)|X1i, Yi(A1B1)
]
= κ21
pi1
P1
E [X1i(Yi(A1B1)− µ111)(Yi(A1B1)− µ112)]
= κ1
pi1
P1
[σ2A1B1 + µ
2
A1B1
− µ111µA1B1 − µ112µA1B1 + µ111µ112]
= κ1
pi1
P1
[σ2A1B1 + (µA1B1 − µ111)(µA1B1 − µ112)].
Since, from Equation (2.2), (µA1B1−µ111) = µA1B1−pi1µA1B1−(1−pi1)µA1C1 = (1−pi1)(µA1B1−
µA1C1) and (µA1B1−µ112) = (1−pi1)(µA1B1−µA1C2), it follows that the asymptotic covariance
of µˆ111 and µˆ112 is given by
cov(µˆIPWN111 , µˆ
IPWN
112 ) =
κ1
n
pi1
P1
[σ2A1B1 + (1− pi1)2(µA1B1 − µA1C1)(µA1B1 − µA1C2)]. (2.9)
A similar derivation could be employed to compute other covariances. Let Σ = var(ψi),
where ψi is the vector of eight influence functions ψjkli, j, k, l = 1, 2, denote the variance-
covariance matrix where Equation (2.7) is used to form the diagonal elements and Equation
(2.9) is used to form the off-diagonal entries, respectively.
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2.4 OVERALL SAMPLE SIZE
The hypothesis of interest is whether there is a strategy-specific mean difference. The null
hypothesis is H0 : µ111=µ112=µ121=µ122=µ211=µ212=µ221=µ222, which is written as a linear
equation H0 : Cµ=0, where
C =

1 −1 0 0 0 0 0 0
1 0 −1 0 0 0 0 0
1 0 0 −1 0 0 0 0
1 0 0 0 −1 0 0 0
1 0 0 0 0 −1 0 0
1 0 0 0 0 0 −1 0
1 0 0 0 0 0 0 −1

,
and µ = [µ111, µ112, µ121, µ122, µ211, µ212, µ221, µ222]
T . Under the null hypothesis, the statistic
nµˆTCT [CΣˆCT ]−1Cµˆ follows a central chi-square distribution with degree of freedom equal
to 7, the number of rows of the contrast matrix C. Here µˆ and Σˆ denote estimated mean
vector and covariance matrix given by,
µˆT = [µˆ111, µˆ112, µˆ121, µˆ122, µˆ211, µˆ212, µˆ221, µˆ222] ,
Σˆ =
 Σˆ1 0˜
0˜ Σˆ2
 ,
where
Σˆ1 =

σˆ2111 σˆ111,112 σˆ111,121 σˆ111,122
σˆ112,111 σˆ
2
112 σˆ112,121 σˆ112,122
σˆ111,112 σˆ121,112 σˆ
2
121 σˆ121,122
σˆ122,111 σˆ122,112 σˆ122,121 σˆ
2
122
 ,
Σˆ2 =

σˆ2211 σˆ211,212 σˆ211,221 σˆ211,222
σˆ212,211 σˆ
2
212 σˆ212,221 σˆ212,222
σˆ211,212 σˆ221,212 σˆ
2
221 σˆ221,222
σˆ222,211 σˆ222,212 σˆ222,221 σˆ
2
222
 ,
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0˜ =

0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
 ,
where µˆjkl is defined in Equation (2.7), σˆ
2
jkl is obtained by substituting estimates of param-
eters on the RHS in Equation (2.7). For example,
σˆ2111 =
κˆ1
n
[
pˆi1
Pˆ1
{
σˆ2A1B1 + (µˆ111 − µˆA1B1)2
}
+
(1− pˆi1)
Qˆ1
{
σˆ2A1C1 + (µˆ111 − µˆA1C1)2
}]
,
where
κˆ1 =
n∑n
i=1X1i
,
pˆi1 =
∑n
i=1 X1iRi∑n
i=1X1i
,
µˆA1B1 =
∑n
i=1 X1iRiZ1iYi∑n
i=1X1iRiZ1i
,
σˆ2A1B1 =
∑n
i=1(X1iRiZ1iYi − µˆA1B1)2
(
∑n
i=1 X1iRiZ1i)(
∑n
i=1X1iRiZ1i − 1)
,
Qˆ1 =
∑n
i=1X1i(1−Ri)Z
′
1i∑n
i=1X1i(1−Ri)
,
and
Pˆ1 =
∑n
i=1X1iRiZ1i∑n
i=1X1iRi
.
Under the alternative hypothesis, the test statistic follows a non-central chi-squared
distribution with the same degrees of freedom and a non-centrality parameter λ, where
λ = nµTCT [CΣCT ]−1Cµ.
Consequently, a straightforward manipulation leads to a sample size formula,
n =
λ
µTCT [CΣCT ]−1Cµ
. (2.10)
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To use the sample size formula in Equation (2.10), for a given power, we note that the power
of the Wald test is the probability that we reject the null hypothesis, i.e., the probability
that the test statistic is greater than the critical value. Thus,
power = P (χ2df=7,λ ≥ χ2df=7,1−α) = 1− P (χ2df=7,λ ≤ χ2df=7,α), (2.11)
where α is the level of significance of the test. For a given power and α, we can solve
Equation (2.11) for λ. Having obtained λ, the sample size needed for achieving a given power
is obtained by plugging in appropriate strategy means under the alternative hypothesis and
their assumed variance-covariance matrix into the sample size expression above.
The knowledge of subgroup means and variances in the population will allow the com-
putation of covariance terms.
2.5 POWERING PAIRWISE COMPARISONS
Above we developed a sample size formula for a global test that provides evidence that there
are differences among at least one pair of strategy means. Next, it is natural to focus on
pairwise comparisons and ask which strategy means are different. A popular two-sample
pairwise test is the t-test. A sample size based on the usual t-test would not apply directly
since the assumption of independence among strategy means does not hold. When strategies
share first stage treatment, a pairwise treatment comparison should consider the between-
strategy covariances in the traditional t-test based sample size formula. Suppose we are
interested in the sample size of a test that truly rejects the null hypotheses at a pre-specified
level of significance (α) and a given power. For instance, there are 8 regimes and 28 pairwise
comparisons for Design 1. One possible pairwise comparison would be,
H0 : µ111 − µ112 = δ1.
For each test different sample sizes are required to detect a difference between each pairwise
comparison. To control type I error, Bonferroni correction can be used. That is, for a two-
sided test the level of significance for each hypothesis will be α/g, where g is the total number
23
of pairwise comparisons. The aim is to compute the sample sizes for each pairwise comparison
and then select maximum of the set of sample sizes that powers a test to identify difference
between strategy means. The sample size formula that accounts dependency among strategy
means is,
n =
[σ2jkl + σ
2
j′k′ l′ − 2σjkl,j′k′ l′ ][Z1−α/2g + Z1−β]2
[µjkl − µj′k′ l′ ]2
, j, k, l = 1, 2 (2.12)
where σ2jkl, σ
2
j′k′ l′ , and σjkl,j′k′ l′ are obtained using Equations (2.7) and (2.9); µjkl and µj′k′l′
are the strategy means under the alternative hypothesis. If the strategy means do not share
the same initial treatments, the between-strategy means covariance is zero and the sample
size formula (2.12) would mimic the one required for independent two-sample t-test.
Equation (2.12) has a more general use than it apparently implies. For example, suppose
prior to designing the trial, researchers focus on g1 ≤ g specific pairwise comparisons. Then
the sample size for pairwise comparisons can be calculated using a level of significance α
g1
to ensure that the experiment-wise error is maintained at α for a pairwise comparison of g1
pairs. Since the variance-covariance formula depends on the randomization probabilities, the
researcher could potentially use randomization probabilities that allocate more observations
to the strategies of interest. The other (g−g1) pairwise comparisons could remain unpowered
but essentially provide valuable information for future studies.
Methods developed in Sections 3 and 4 can easily be applied to Designs 2 and 3. For
example, for Design 2, to test the overall hypothesis H0 : µ111 = µ112 = µ221 = µ222, it is
written as a linear equation H0 : Cµ=0, where
C =
 1 −1 0 01 0 −1 0
1 0 0 −1
 ,
and µ = [µ111, µ112, µ221, µ222]
T . The variance-covariance matrix Σ can be computed in a
similar manner as Design 1 by replacing with 4 diagonal estimated mean strategy variances
and 4 off-diagonal estimated covariances among strategy means. That is,
Σ =

σ2111 σ111,112 0 0
σ112,111 σ
2
112 0 0
0 0 σ2211 σ211,212
0 0 σ212,211 σ
2
212
 .
Note that in Design 2, since there is only one treatment option for the responders, P1=1.
24
2.6 SIMULATION STUDY AND RESULTS
To evaluate the performance of the overall sample size formula, we conducted a number of
simulations to see if the empirical power for detecting the alternative hypothesis is close to
the nominal power. We presented four scenarios for each of the three designs in Tables 1, 2
and 3 by varying the nominal power, response rates and probabilities of second treatment
assignment for responders (Pk) and non-responders (Ql). For each subject in the popula-
tion, Yi(AjBk) and Yi(AjCl) follow normal distribution with means µAjBk and µAjCl , and
variances σ2AjBk and σ
2
AjCl
, respectively for j, k, l = 1, 2. The response status Ri was gener-
ated from a Bernoulli distribution with probability (response rate) pi1 to treatment A1 and
pi2 to treatment A2. For each scenario we generated 10000 samples using the three designs.
The methods described so far are explained via Design 1, however, the formulas can be
applied to Designs 2 and 3. There are six pairwise comparisons for Design 2 and fifteen for
Design 3. Tables 4 and 5 show the pairwise sample size computation for Designs 2 and 3.
Tables 1, 2 and 3 demonstrate sample size computation for different scenarios by assuming
certain values for population parameters. Design 1 assumes subgroup means: µAjB1 =
µAjC2 = 15, µAjC1 = 20, µAjB2 = 22; subgroup variances: σ
2
AjBk
= 62, σ2AjCl = 8
2, for j, k, l =
1, 2. Subgroup variances are assumed to be the same for all designs considered. Depending
on a specific design and scenario considered, the following range of response proportions pij’s
are assumed: 0.2, 0.3, 0.5, 0.6 and 0.7. Similarly, depending on a specific design the following
P1 and Q1 are assumed. Probability of treatment assignment for responders, P1, is assumed
to be 0.5, 0.7, 0.9 and 1. For non-responders, Q1(= 1 − Q2), is assumed to be 0.5, 0.7,
0.9. Design 2 assumes the following subgroup means: µA1B1 = 15, µA2B1 = 17, µAjC2 = 15,
µA1C1 = 20, µA2C1 = 22, for j, k, l = 1, 2. Design 3 assumes the following subgroup means:
µA1B1 = 15, µA2B1 = 17, µA3B1 = 19, µAjC2 = 15, µA1C1 = 20, µA2C1 = 22, µA3C2 = 24, for
j, k, l = 1, 2, 3. The parameter values were chosen following those from Ko and Wahed [11].
The sample size changes as the values for pij, Pl, Ql, and power vary. The strategy means
differ for each scenario in each table. In each scenario, having obtained the appropriate
sample size using our formula, we evaluate the power of the Wald tests in rejecting the null
hypothesis of no difference in treatment means when the strategies have different means. The
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effect size is computed using the Mahalanobis distance (MD). One useful property of the MD
is that it takes into account the correlation in the data. Effect sizes are common measures
in psychology and other disciplines where they are useful in calculating and interpreting
power especially if more than two groups are involved. Effect size estimates add validity to
interpretation of results. The magnitude of effect sizes would capture experimental effects
by protecting guaranteed significance due to large sample size [5].
The first row of Scenario 1 in Table 1 assumes strategy means µ111 = 17.5 µ112 = 15,
µ121 = 21, µ122 = 18.5, µ211 = 17.5, µ212 = 15, µ221 = 21, µ222 = 18.5 when response rates pi1,
pi2 were taken to be both 0.5; P1 and Q1 are assumed to be 0.5. 70 subjects would be required
to detect the resulting effect size of 0.21 with power 80% at α = 0.05. The empirical power
is 85% which is slightly inflated compared to the nominal power of 80% used to compute the
sample size. Row 3 of the same scenario shows that the empirical power of 92% is close to
the nominal value of 90%. Similar patterns follow for all the rows in Scenarios 2, 3 and 4. If
we observe across all scenarios (from 4 to 1), we note a small degree of increase in empirical
power when P1 increases.
The first row of Scenario 1 in Design 2 (Table 2) assumes strategy means µ111 = 17.5,
µ112 = 15, µ211 = 19.5, µ212 = 16 when response rates pi1, pi2 were taken to be both 0.5;
P1=1 and Q1=0.5. 142 subjects would be required to detect the resulting effect size of 0.08
with power 80% at α = 0.05. The empirical power is 81% which is very close to the nominal
power of 80% used to compute the sample size. Row 4 of scenario 3 shows that the empirical
power of 93% is slightly inflated compared to the nominal value of 90%. For various response
rates, the empirical power for each case in scenarios 1 to 3 nearly attain the nominal power.
This indicates that the sample sizes calculated for Design 2 ensure enough power to detect
differences among the four strategy means.
The first row of Scenario 1 in Design 3 (Table 3) assumes strategy means µ111 = 17.5,
µ112 = 15, µ211 = 19.5, µ212 = 16, µ311 = 21.5, µ312 = 17 when response rates pi1, pi2, pi3
were taken to be all 0.5. 108 subjects would be required to detect the resulting effect size
of 0.12 with power 80% at α = 0.05. The empirical power is 83% which is slightly larger
than the nominal power of 80% used to compute the sample size. We note that for small
changes in response rates, sometimes the sample sizes do not change or change only slightly.
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Table 1: Overall sample size for Design 1.
Overall Empirical Effect Size
Scenario pi1 pi2 P1 Power Sample Size Power (Mahalanobis Distance)
1 0.5 0.5 0.5 0.8 70 0.84 0.21
0.5 0.5 0.7 0.8 79 0.85 0.18
0.5 0.5 0.5 0.9 89 0.92 0.21
0.5 0.5 0.8 0.9 120 0.92 0.15
2 0.2 0.5 0.5 0.8 83 0.82 0.17
0.2 0.5 0.7 0.8 92 0.83 0.16
0.2 0.5 0.5 0.9 106 0.9 0.17
0.2 0.5 0.8 0.9 134 0.92 0.14
3 0.7 0.5 0.5 0.8 62 0.85 0.23
0.7 0.5 0.7 0.8 71 0.85 0.20
0.7 0.5 0.5 0.9 79 0.92 0.23
0.7 0.5 0.7 0.9 91 0.92 0.20
4 0.2 0.7 0.5 0.8 72 0.84 0.20
0.2 0.7 0.7 0.8 82 0.84 0.18
0.2 0.7 0.5 0.9 92 0.91 0.20
0.2 0.7 0.7 0.9 104 0.92 0.18
Sample size computation and simulation of empirical power (# replications=10000) for De-
sign 1 where Q1 = 0.5, subgroup means: µAjB1 = µAjC2 = 15, µAjC1 = 20, µAjB2 = 22;
subgroup variances: σ2AjBk = 6
2, σ2AjCl = 8
2, for j, k, l = 1, 2. Hypothesis of interest is H0 :
µ111=µ112=µ121=µ122=µ211=µ212=µ221=µ222; α = 0.05.
Alternative is true with means: Scenario 1: µ111 = 17.5, µ112 = 15.0, µ121 = 21.0, µ122 = 18.5,
µ211 = 17.5, µ212 = 15.0, µ221 = 21.0, µ222 = 18.5
Scenario 2: µ111 = 19.0, µ112 = 15.0, µ121 = 20.4, µ122 = 16.4, µ211 = 17.5, µ212 = 15.0,
µ221 = 21.0, µ222 = 18.5
Scenario 3: µ111 = 16.5, µ112 = 15.0, µ121 = 21.4, µ122 = 19.9, µ211 = 17.5, µ212 = 15.0,
µ221 = 21.0, µ222 = 18.5
Scenario 4: µ111 = 19.0, µ112 = 15.0, µ121 = 20.4, µ122 = 16.4, µ211 = 16.5, µ212 = 15.0,
µ221 = 21.4, µ222 = 19.9
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Table 2: Overall sample size for Design 2.
Overall Empirical Effect Size
Scenario pi1 pi2 Q1 Power Sample Size Power (Mahalanobis Distance)
1 0.5 0.5 0.5 0.8 142 0.81 0.08
0.5 0.5 0.7 0.8 156 0.82 0.07
0.5 0.5 0.5 0.9 185 0.91 0.08
0.5 0.5 0.9 0.9 344 0.92 0.04
2 0.2 0.5 0.5 0.8 130 0.81 0.08
0.2 0.5 0.7 0.8 144 0.82 0.07
0.2 0.5 0.5 0.9 169 0.91 0.08
0.2 0.5 0.9 0.9 448 0.92 0.03
3 0.7 0.5 0.5 0.8 143 0.82 0.08
0.7 0.5 0.7 0.8 143 0.83 0.08
0.7 0.5 0.5 0.9 186 0.91 0.08
0.7 0.5 0.9 0.9 241 0.93 0.06
4 0.7 0.2 0.5 0.8 94 0.82 0.12
0.7 0.2 0.7 0.8 88 0.84 0.12
0.7 0.2 0.5 0.9 122 0.9 0.12
0.7 0.2 0.9 0.9 131 0.94 0.11
Sample size computation and simulation of empirical power (# replications=10000) for De-
sign 2 where P1 = 1, subgroup means: µA1B1 = 15, µA2B1 = 17, µAjC2 = 15, µA1C1 = 20,
µA2C1 = 22; subgroup variances: σ
2
AjBk
= 62, σ2AjCl = 8
2 for j, k, l = 1, 2. Hypothesis of
interest is H0 : µ111=µ112=µ211=µ212.
Alternative is true with means: Scenario 1: µ111 = 17.5, µ112 = 15.0, µ221 = 19.5, µ222 = 16.0
Scenario 2: µ111 = 19.0, µ112 = 15.0, µ221 = 19.5, µ222 = 16.0
Scenario 3: µ111 = 16.5, µ112 = 15.0, µ221 = 19.5, µ222 = 16.0
Scenario 4: µ111 = 16.5, µ112 = 15.0, µ221 = 21.0, µ222 = 15.4
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Table 3: Overall sample size for Design 3.
Overall Empirical Effect Size
Scenario pi1 pi2 Power Sample Size Power (Mahalanobis Distance)
1 0.5 0.5 0.8 108 0.83 0.12
0.2 0.5 0.8 111 0.83 0.12
0.5 0.5 0.9 139 0.91 0.12
0.2 0.5 0.9 142 0.91 0.12
2 0.2 0.2 0.8 95 0.84 0.14
0.2 0.6 0.8 116 0.84 0.11
0.2 0.2 0.9 122 0.92 0.14
0.2 0.6 0.9 149 0.91 0.11
3 0.3 0.5 0.8 111 0.83 0.12
0.3 0.6 0.8 116 0.82 0.11
0.3 0.5 0.9 142 0.91 0.12
0.3 0.6 0.9 149 0.92 0.11
4 0.4 0.5 0.8 110 0.83 0.12
0.4 0.6 0.8 115 0.82 0.11
0.4 0.5 0.9 141 0.92 0.12
0.4 0.6 0.9 148 0.91 0.11
Sample size computation and simulation of empirical power (# replications=10000) for De-
sign 3 where P1 = 1, subgroup means: µA1B1 = 15, µA2B1 = 17, µA3B1 = 19, µAjC2 = 15,
µA1C1 = 20, µA2C1 = 22, µA3C1 = 24; subgroup variances: σ
2
AjBk
= 62, σ2AjCl = 8
2 for
j, k, l = 1, 2, 3. Response rate for induction treatment A3 is assumed to be 50%. Hypothesis
of interest is H0 : µ111 = µ113 = µ221 = µ223 = µ331 = µ332.
Alternative is true with means: Scenario 1: µ111 = 17.5, µ112 = 15.0, µ221 = 19.5, µ222 = 16.0,
µ331 = 21.5, µ332 = 17.0
Scenario 2: µ111 = 19.0, µ112 = 15.0, µ221 = 21.0, µ222 = 15.4, µ331 = 21.5, µ332 = 17.0
Scenario 3: µ111 = 18.5, µ112 = 15.0, µ221 = 19.5, µ222 = 16.0, µ331 = 21.5, µ332 = 17.0
Scenario 4: µ111 = 18.0, µ112 = 15.0, µ221 = 19.5, µ222 = 16.0, µ331 = 21.5, µ332 = 17.0
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Table 4: Pairwise sample size computation for Design 2.
Overall MC Not Corrected
Adjusted for
Hypothesis Sample Size Multiple Comparison δi
H1 : µ111−µ112=δ1 532 345 2.5
H2 : µ111−µ221=δ2 1107 717 -2.0
H3 : µ111−µ222=δ3 1882 1220 1.5
H4 : µ112−µ221=δ4 207 134 -4.5
H5 : µ112−µ222=δ5 4008 2598 -1.0
H6 : µ221−µ222=δ6 280 181 3.5
Subgroup means: µA1B1 = 15, µA2B1 = 17, µA1C1 = 20, µA1C2 = 15, µA2C1 = 22, µA2C2 = 15;
subgroup variances: σ2AjBk = 6
2, σ2AjCl = 8
2 for j, k, l = 1, 2. Here pi1=0.5, pi2=0.5, P1=1,
Q1=0.5, and power=0.8.
For example, row 4 of scenarios 2 and 3 have the same sample size (149). The sample size
did not change as pi1 changed slightly from 0.2 to 0.3.
In many clinical trials, testing of an overall hypothesis may not be of primary interest,
rather some or all of the pairwise comparisons are. To show how the sample size for a SMAR
trial is determined in such cases, we present the sample sizes required for Design 2 when
all six pairwise comparisons are powered simultaneously in the second column of Table 4.
The third column provides the sample sizes when individual tests are powered. For example,
under the setting described in Table 4, Design 2 requires 4008 patients to power all pairwise
comparisons. However, if the interest, for example, is in powering the single hypothesis
H0 : µ111 = µ112 leaving other pairs as exploratory, the trial could be conducted using a
sample as small as 345. Similarly, Table 5 provides sample sizes for Design 3 when fifteen
pairwise comparisons are powered simultaneously (Column 2) and when only three pairwise
comparisons are considered (Column 3). From Column 2, Design 3 requires 30,704 patients
(maximum of the sample sizes) to power all pairwise comparisons. However, if the interest
is in powering only three pairwise hypotheses such as H0 : µ112 = µ113, H0 : µ112 = µ221, and
H0 : µ112 = µ223, the trial would require a sample size of 2,441. On the other hand, if the
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Table 5: Pairwise sample size computation for Design 3.
Overall MC Partially MC
Adjusted Adjusted
Hypothesis Sample Size Sample Size δi
H1 : µ112−µ113=δ1 941 690 2.5
H2 : µ112−µ221=δ2 1955 1435 -2.0
H3 : µ112−µ223=δ3 3326 2441 1.5
H4 : µ112−µ331=δ4 489 359 -4.0
H5 : µ112−µ332=δ5 30704 22535 0.5
H6 : µ113−µ221=δ6 366 269 -4.5
H7 : µ113−µ223=δ7 7082 5198 -1.0
H8 : µ113−µ331=δ8 176 129 -6.5
H9 : µ113−µ332=δ9 1819 1335 -2.0
H10 : µ221−µ223=δ10 494 362 3.5
H11 : µ221−µ331=δ11 1955 1435 -2.0
H12 : µ221−µ332=δ12 1228 901 2.5
H13 : µ223−µ331=δ13 247 182 -5.5
H14 : µ223−µ332=δ14 7339 5386 -1.0
H15 : µ331−µ332=δ15 314 230 4.5
Subgroup means: µA1B1 = 15, µA2B1 = 17, µA3B1 = 19, µA1C1 = 20, µA1C2 = 15, µA2C1 = 22,
µA2C2 = 15, µA3C1 = 24, µA3C2 = 15; subgroup variances: σ
2
AjBk
= 62, σ2AjCl = 8
2 for j, k, l =
1, 2, 3. Here pi1=0.5, pi2=0.5, P1=1, Q1=0.5, and power=0.8. Second column provides sample
size which powers all pairwise comparisons whereas the third column assumes that only three
of the fifteen hypotheses are of interest.
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interest is only in comparing the three pairs, H4, H6, and H8 then the sample size required
will be n = 359.
Outcomes in the above simulation scenarios were generated from a normal distribution.
We wanted to conduct the sensitivity of our formula to non-normal responses. To do this,
we further generated data from logistic (symmetric) and gamma (skewed) distributions and
calculated the empirical power based on the sample size calculated using Equation(2.10).
Basically, we selected one row from each scenario of Tables 1 to 3 to perform sensitivity
analysis of our formula using data from the logistic and gamma distributions ensuring the
same means and variances for the subpopulations and keeping all other parameters the same.
From each table, we selected the first row for Scenarios 1 and 3 while we chose the fourth
row for Scenarios 2 and 4. Therefore, the results presented in Table 6 have twelve rows
in total. In general, the nominal power is maintained and is consistent across the three
distributions. This shows that our sample size formula is robust to the misspecification of
outcome distribution.
2.7 DISCUSSION
Complex multi-stage diseases require decision-based multi-stage treatments depending on the
response to prior-stage treatments. SMAR designs provide efficient and unbiased inference
to compare staged strategies for complex conditions. We presented a sample size formula
that is applicable for various SMAR designs to ensure adequately powered comparisons of
these treatment strategies. The usual design is to randomize responders (or non-responders)
to available treatments. A slight variation to that is a design where responders (or non-
responders) would not be randomized any further in the second stage. Designs 2 and 3 are
such examples. In Design 2, only the non-responders are randomized to C1 or C2 and C
′
1 or
C
′
2 respectively depending on whether they received A1 or A2 in the first stage. Responders
would stay on the same first stage treatment. Equivalently, responders will be randomized
with probability 1 to whatever treatment they received in the first stage. There are four
strategies resulting from this design and the sample size required to detect differences among
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Table 6: Robustness of the Sample Size Formula against misspecification of out-
come distributions.
Empirical Empirical Empirical
Overall Power: Power: Power:
Design Scenario pi1 pi2 P1 Q1 Power Sample Size Normal Gamma Logistic
Design 1 1 0.5 0.5 0.5 0.5 0.8 70 0.84 0.86 0.86
2 0.2 0.5 0.8 0.5 0.9 134 0.92 0.93 0.93
3 0.7 0.5 0.5 0.5 0.8 62 0.85 0.86 0.87
4 0.2 0.7 0.7 0.5 0.9 104 0.92 0.92 0.92
Design 2 1 0.5 0.5 1 0.5 0.8 142 0.81 0.83 0.82
2 0.2 0.5 1 0.9 0.9 448 0.92 0.91 0.91
3 0.7 0.5 1 0.5 0.8 143 0.82 0.85 0.83
4 0.7 0.2 1 0.9 0.9 131 0.94 0.96 0.94
Design 3 1 0.5 0.5 1 0.5 0.8 108 0.83 0.86 0.85
2 0.2 0.6 1 0.5 0.9 149 0.91 0.93 0.92
3 0.3 0.5 1 0.5 0.8 111 0.83 0.86 0.85
4 0.4 0.6 1 0.5 0.9 148 0.91 0.93 0.92
For Design 1 the following parameter values were considered: Q1 = 0.5, subgroup means:
µAjB1 = µAjC2 = 15, µAjC1 = 20, µAjB2 = 22; subgroup variances: σ
2
AjBk
= 62, σ2AjCl = 8
2, for
j, k, l = 1, 2. The hypothesis tested is H0 : µ111=µ112=µ121=µ122=µ211=µ212=µ221=µ222; α =
0.05. For Design 2 the following parameter values were considered: P1 = 1, subgroup means:
µA1B1 = 15, µA2B1 = 17, µAjC2 = 15, µA1C1 = 20, µA2C1 = 22; subgroup variances: σ
2
AjBk
=
62, σ2AjCl = 8
2 for j, k, l = 1, 2. The hypothesis tested is H0 : µ111=µ112=µ211=µ212. For
Design 3 the following parameter values were considered: P1 = 1, subgroup means: µA1B1 =
15, µA2B1 = 17, µA3B1 = 19, µAjC2 = 15, µA1C1 = 20, µA2C1 = 22, µA3C2 = 24; subgroup
variances: σ2AjBk = 6
2, σ2AjCl = 8
2 for j, k, l = 1, 2, 3. Response rates to induction treatment
A3 is assumed to be 50%. The hypothesis tested is H0 : µ111=µ113=µ221=µ223=µ331=µ332.
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the four strategies is computed. In Design 3 each patient is randomized to a set of treatments
(A1, A2, A3) in the first stage and these treatments are continued until they fail due to disease
worsening. The patient is then re-randomized among a set of the same first stage treatments
with the exception of the treatment s/he received initially. There are six strategies of interest
in this design. We showed in the simulation how to compute sample size formula for this
design and showed that the formula ensures nominal power under various scenarios involving
many outcome distributions.
In contrast to our formula, Murphy’s [22] formula is not applicable to designs powering
multi-strategy comparison or to designs comparing strategies that share the same initial
treatments commonly referred to as shared-path strategies [10] or overlapping strategies [3].
Moreover, their formula requires specifying the variance of the response under the strategies
being compared, although the effect sizes can be specified per standard deviations of mean
difference assuming equal variance across strategies.
Dawson and Lavori [3, 4] provide a sample size formula for comparing pairs of overlap-
ping or non-overlapping/treatment strategies based on semiparametric efficient variances.
The formula requires one to specify the variance of the response under each strategy and
the variance inflation factor, the latter depending on the coefficient of determinations based
on the regression of counterfactual strategy response on stage-specific states. Correct spec-
ification of such quantities is difficult, if not impossible, in the absence of a similar SMAR
trial. However, when correctly specified, Dawson and Lavori’s formula provide smaller sam-
ple sizes than those proposed in Murphy [22] or the ones provided here. One advantage
of both Murphy [22] and Dawson and Lavori’s [3, 4] formula over our method is that they
can be applied to compare strategies from SMAR trial with more than two stages. How-
ever, like Murphy’s formula, Dawson and Lavori’s formula also focuses on comparing pairs
of treatment strategies.
The simplicity of our procedure compared to Dawson and Lavori [3] (even in the two-stage
SMAR trial settings) relies on the specification of the parameters. Our formula requires one
to specify sub-group-specific means and variances. Our sample size formula requires spec-
ification of subgroup means and variances for patients following different treatment paths.
These parameters are usually available from observational studies or stage-specific individual
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non-SMAR trials. For example, there are many cancer clinical trials that compare frontline
treatments (e.g. Estey et al. [15]). Even though such trials are terminated once the recruit-
ment is over and the primary endpoint is observed or the trial period ends, patients are often
followed and medication information (salvage treatments used) is collected for patients who
become resistant to frontline therapy or for patients with disease progression. The collection
of salvage treatment information is often done only for the purpose of safety, however, such
information allows the researchers to obtain meaningful information on subgroup means and
variances based on the salvage therapies received within each frontline treatments. Mental
health and other clinical research by their very nature, are concerned with sequences of treat-
ments and hence the means and variances of responses under a particular treatment sequence
are most likely to be available from observational studies or from electronic medical records.
Fortunately, there are already existing SMAR trials in mental health (STAR*D [33], CATIE
[35]) that can provide useful information on subgroups to be used in future trial design.
The Murphy [22] and Dawson and Lavori [3] methods require fewer unknown quantities
to be specified compared to what is required by our formula; our parameters are basically
means and variances of response among subpopulations. Generally, these parameters can
be obtained from pilot studies, non-SMAR trials or observational studies. Therefore, these
parameters are less likely to be mis-specified as compared to the parameters in Murphy’s
[22] and Dawson and Lavori’s [3] methods. Moreover, our focus is to compare multiple
treatment strategies for which specification of effect size does not necessarily reduce the
number of unknown parameters.
The Oetting et al. [25] sample size formula for comparing two strategies is derived
under the assumption that response rates are the same across the two first stage treatments.
While a sensitivity analysis was carried out in the simulation, this assumption may not be
reasonable in practice. Finally, our formula does not address the issue of finding an optimal
treatment strategy, which is a separate issue that is dealt with in Oetting et al. [25].
Future research could investigate sample size formulas for various k-stage designs with
emphasis on specific and meaningful number of strategies. Issues of missing data is another
design concern in SMAR trials that needs to be addressed.
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3.0 ANALYSIS OF SEQUENTIALLY RANDOMIZED TRIALS THROUGH
ARTIFICIAL RANDOMIZATION
3.1 INTRODUCTION
Treatment of patients whose disease severity change over time is best managed by employing
strategies that treat patients dynamically. Naturally, administering treatments in steps
according to changing disease phases would lead to better management and likely better
outcome. Psychiatrists commonly treat mental illnesses by first stabilizing the patient in the
first stage and then preventing relapse in the second stage [33]. Treatment strategies that
are adapted to patients’ response status are therefore attractive to clinicians and researchers
alike. Public health interest in adaptive treatment strategies (ATS) is growing basically for
two reasons:
i. Increasingly convincing evidence are becoming available that using adaptive treatment
strategies, overall health outcome could be improved and better compared to traditional
once-and-for-all treatments, and
ii. ATSs are implemented in a manner a patient’s disease is naturally managed.
Research in the area of ATS has so far focused on comparison of adaptive treatment
strategies and estimation of optimal strategy. The crux of the problem in this chapter is
how to compare strategy means that account for baseline covariates. Regression methods
such as multiple linear, logistic, or survival (Cox or accelerated failure) regression that allow
for comparison of treatment strategies flexibly adjusting for baseline covariates are not as
straight-forward to apply in SMART designs. This is because a patients in a SMAR trial
can belong to multiple strategies making it challenging, if not impossible to apply regression
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Table 7: A hypothetical data set from a two-stage SMAR trial.
Patient Initial Treatment Response Status Second Treatment A1B1 A1B2 A2B1 A2B2
1 A1 No B1 1 0 0 0
2 A1 Yes NA 1 1 0 0
3 A1 No B2 0 1 0 0
4 A2 Yes B1 0 0 1 0
5 A2 Yes NA 0 0 1 1
6 A2 No B2 0 0 0 1
techniques. To clarify this, let us consider a two-stage SMAR design similar to the one
described in Figure 3 on page 12. Four strategies in this design are AjBk which denotes “treat
with Aj followed by Bk if he/she is a non-responder (j, k = 1, 2)”. One may be tempted
to compare the four strategies: A1B1, A1B2, A2B1, A2B2 using a regression model. Note
that a patient responding to A1 is, by definition, consistent with both strategies A1B1 and
A1B2 which poses a challenge for data analysts as it violates basic assumptions of regression
modeling of unique group membership. As shown in [37], Table 7 summarizes a hypothetical
situation whereby a patient can belong to multiple strategies. In this hypothetical data set
we present 6 patients participating in a trial represented in Figure 3 (page 12). It gives the
initial treatment assignment, response status, second treatment assignment, and an indicator
(0 or 1) to indicate if that particular patient belongs to one of the four specific strategies. For
instance, patient 2 is a responder to initial treatment A1. Therefore, his or her data could
be used to draw inference for two strategies namely, A1B1 and A1B2. Similarly, patient 5
is a responder to A2 whose treatment path is consistent with following strategies A2B1 and
A2B2. Thus, the same patient can have a treatment trajectory that makes him eligible to be
counted in multiple strategies poses a challenge for the analyst to use regression modeling
techniques. Hence, we propose an “artificial randomization” technique to make the data
appear that each subject belongs to a unique strategy. This will enable us to use regular
regression methods by inserting treatment strategy indicators as covariates in a regression
model along with other covariates.
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Table 8: A hypothetical data set from a two-stage SMAR trial: Illustrating
Artificial Randomization.
Patient Initial Treatment Response Status Second Treatment Z∗ A1B1 A1B2 A2B1 A2B2
1 A1 No B1 B1 1 0 0 0
2 A1 Yes NA B1 1 0 0 0
3 A1 No B2 B2 0 1 0 0
4 A2 No B1 B1 0 0 1 0
5 A2 Yes NA B2 0 0 0 1
6 A2 No B2 B2 0 0 0 1
G-computation [27] and inverse probability weighting (IPW) [18] are commonly used to
estimate treatment regime effects and thus can be used for Wald-type hypothesis testing to
compare strategy means. Unlike G-computation, IPW has become popular in applications
for its ease of implementation and generality. For example, IPW does not estimate or make
assumptions about distributions of intermediate outcomes. Various papers have suggested
methods to compare different treatment strategies using IPW. Except for the limited work
of Hernan et al., and Tang and Wahed [8, 38], most of these methods do not allow regression
to adjust for baseline covariates. Using observational data, Hernan et al. [8] applied a Cox
regression with artificial censoring to compare different two treatment strategies. Due to wide
range of possible treatment regime options, observations were routinely artificially censored
if they depart from the pre-specified regimes of interest. Hernan’s approach is a motivation
to build a unified regression model with the option of adjusting for covariates and interaction
terms (between covariates and treatment strategies) in a model. Using IPW in a two-stage
randomization setting, Lokhnygina and Helterbrand [17] derived an estimator for the log-
hazard and a score test to compare treatment strategies under Cox model. However, this is
limited to the comparison of a pair of treatment regimes without adjusting for time-varying
treatment effects or other auxiliary variables. Tang and Wahed [38] suggested modeling each
treatment strategy using Cox regression model that adjusts for both time dependent and time
independent covariates. They fit a stratified Cox model that allows the underlying hazard to
vary across strategies. Model comparisons among treatment strategies is performed using log
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ratio of estimated cumulative hazards. Their approach to model each strategy and make a
statistical comparison across strategies is the only work known thus far to compare strategies
by adjusting for covariates.
We propose a consistent simple multiple artificial randomization tool (SMART) estimator
that combines ‘artificially randomized’ estimators according to Rubin’s (1977, 1987) [31, 32]
multiple imputation method. Subsequently, the ‘artificial randomization’ approach is utilized
in regression models to compare strategies adjusting for baseline covariates, and hence inform
further useful strategies.
This chapter is organized as follows. In Section 3.2, we describe counterfactual and ob-
served outcomes followed by an introduction to artificial randomization and the proposed
SMART estimator in Section 3.2.1. This estimator is compared with IPW-based estimators
in Section 3.2.2. Within this subsection, we derive model-based and robust variance esti-
mates for each estimator. In Section 3.3, we conduct simulation studies to examine properties
of our proposed estimator with respect to existing estimators. In Section 3.4, we demon-
strate how regression analysis through artificial randomization allows adjusted comparison
of ATSs and helps develop new strategies involving covariates. In Section 3.5.1, we apply
the adopted procedures to the CALGB data and report strategy means, standard errors and
confidence intervals. Appropriately, depending on significant interaction between covariate
and strategies, we define new informative covariate-specific strategies. We wrap up the chap-
ter with results in Section 3.5.2. In the CALGB data the outcome is a survival time but we
treat it as continuous in our methodology and drop censored times. With only few censored
observations (7%) the assumption seems to be reasonable.
3.2 ARTIFICIAL RANDOMIZATION, SMART, AND OTHER
ESTIMATORS
The design described in Figure 3 (page 12) allows estimation of the effect of four treatment
regimes, namely, AjBk; j, k = 1, 2. Let Xji be the assignment indicator for first-stage treat-
ment Aj, where Xji = 1, if the i
th patient is randomized to Aj, j = 1, 2; i = 1, 2, ..., n; 0
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otherwise. The indicator for individual response status, Rji, is 1 for responders and 0 for
non-responders to Aj, j = 1, 2; i = 1, 2, ..., n. For non-responders, Rji = 0, define variable
Zki to indicate assignment of second-stage treatments, Bk, k = 1, 2; conditional on Rji = 0,
Zki = 1, if the i
th patient receives Bk assignment; 0 otherwise. Assume Vi and Yi to denote
a vector of baseline covariates and the final outcome, respectively.
Inferences from sequentially randomized trials are often facilitated through defining coun-
terfactual outcomes and corresponding expectations [40, 18, 22]. The goal is to estimate,
for example, the mean of the outcome under a given strategy. Let Yi(Aj), j = 1, 2 indi-
cate outcomes under Aj if the patient had received Aj and responded to Aj (and hence
there were no second randomization). Similarly, Yi(AjBk), j, k = 1, 2 denotes outcomes un-
der AjBk, j, k = 1, 2 if the patient had received Aj, j = 1, 2, did not respond and followed
by Bk, k = 1, 2. The potential outcome if patient i follows regime AjBk would then be
Yjki = RjiYi(Aj) + (1 − Rji)Yi(AjBk), j, k = 1, 2; i = 1, ..., n, where Yjki is the potential
outcome for individual i under strategy AjBk. The observed outcome, for patient i following
treatment regime AjBk, is connected to the potential outcome via the following formula,
Yi =
n∑
i=1
2∑
j=1
Xji
{
RjiYi(Aj) + (1−Rji)
2∑
k=1
ZkiYi(AjBk)
}
which is known as the consistency assumption (Assumption 2.3, page 16). As defined in
Chapter 2 (Section 2.3, page 15), the strategy mean is, µjki = pijµAj + (1− pij)µAjBk , where
µAj = E{Y (Aj)} is the sub-group mean of the population receiving Aj followed by Aj,
µAjBk = E{Y (AjBk)} is sub-group mean of the population receiving Aj followed by Bk.
3.2.1 ARTIFICIAL RANDOMIZATION AND THE SMART ESTIMATOR
Analysis of ATSs obtained from SMAR designs has thus far been limited to comparing
means of strategies using Wald-type hypothesis testing. Comparing means of strategies using
regression models that adjust for baseline covariates may be of further interest. However, as
discussed before, such adjustments are not straightforward. The reason is that a regression
model requires subjects belong uniquely to one strategy, which is not the case for SMAR
trials. For example, a responder to A1 is consistent with following strategies A1B1 and
40
A1B2. Therefore, to analyze the data from this specific design using regression or ANOVA
framework, we need to devise a way to attach each subject to a unique strategy. This is
what is the topic of this research.
Since responders are not randomized to further treatments, for the purpose of identify-
ing them to unique strategies, at the analysis stage, we create an artificial randomization
indicator for responders that assigns each responder to one of the second stage treatment,
B1 or B2. It is important to emphasize that responders are artificially randomized for the
sake of statistical analysis after all the data have been accumulated and locked. They are
not re-randomized in the actual trial. The purpose is to uniquely associate each responder
to one of the four strategies AjBk, j, k = 1, 2 so that we can readily employ ANOVA or
regression techniques.
At the analysis stage, we create a randomization indicator, using the same mechanism
that was used to randomize the non-responders. For example, if B1 and B2 were assigned
randomly with probabilities Q1 and 1 − Q1 respectively, then this artificial randomization
indicator Z∗i is defined as,
Z∗i =
 Zi if Ri=0Bernoulli(Q1) if Ri=1
where Bernoulli(Q1) indicates a randomly generated value of a Bernoulli random vari-
able with probability Q1. With this artificial augmentation, the observed data looks like
(Vi, Xi, Ri, Z
∗
i , Yi) , i = 1, 2, ..., n. Define Z
∗
1i = Z
∗
i and Z
∗
2i = 1− Z∗i be the indicators for B1
and B2 (actual or artificial assignment). In this observed data, Xi and Z
∗
i uniquely assigns
a participant to one strategy. For example, patient 2 in Table 8, Xi = 0 and Z
∗
i = 0, we
know that the participant ‘followed’ (treated to have followed) strategy A1B1. With this
‘augmented observed data’ one can easily construct estimators for strategy means or use
regression-based methods to compare strategies adjusting for baseline covariates. Here we il-
lustrate by defining estimates of strategy means. In Section 3.4, we explain how this method
can be adapted for regression or ANOVA.
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Since Xi and Z
∗
i uniquely identifies a participant with a specific strategy, an estimator
of the (j, k)th strategy mean would be
µˆARjk =
∑n
i=1 XjiZ
∗
kiYi∑n
i=1XjiZ
∗
ki
, (3.1)
the simple average of outcome over those who ‘followed’ strategy AjBk. Note that we have
used the superscript ‘AR’ to indicate that this estimator uses artificial randomization. To
show consistency of this estimator, note that,
E(XjiZ
∗
ki) = E [XjiE [Z
∗
ki|Xji]]
= E [XjiE{E(Z∗ki|Xji, Ri)}]
= E [XjiE{RiQk + (1−Ri)Qk}]
= E [XjiQk]
= Qkκj.
where E [Xji] = κj. Also,
E(XjiZ
∗
kiYi) = E [XjiZ
∗
kiYjki] by consistency assumption (Assumption 2.3, page 16),
= E [YjkiE{XjiZ∗ki|Yjki}]
= E [YjkiE(XjiZ
∗
ki)]
= QkE [Yjki]κj
= Qkµjkκj.
Therefore, using the law of large numbers,
µˆARjk =
1
n
∑n
i=1XjiZ
∗
kiYi
1
n
∑n
i=1 XjiZ
∗
ki
p−→ E(XjiZ
∗
kiYi)
E(XjiZ∗ki)
=
Qkµjkκj
Qkκj
= µjk,
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where “
p−→” denotes “convergence in probability”.
Hence, µˆARjk is a consistent estimator of µjk. The artificial randomization procedure
facilitates independent estimation of strategy means to compare ATSs. However, additional
uncertainty introduced into the artificial estimator due to the augmented randomization
indicator needs to be accounted for before it can be compared with existing estimators.
In the spirit of Rubin’s average estimator for multiple imputations, we propose to conduct
multiple artificial randomization and average them to form a single estimator. We refer to
this as a “SMART” (simple multiple artificial randomized tool) estimator. This is similar
to the multiple imputation method that captures uncertainty due to stochastic randomness
introduced via the imputation process. Denote by µˆ
AR(m)
jk the estimate of µjk, from the m
th
“artificially randomized” data set (m = 1, 2, ...,M). The SMART estimate of µjk is the
simple average of the artificial estimates,
µˆSMARTjk =
1
M
M∑
m=1
µˆ
AR(m)
jk . (3.2)
Rubin (1987) [32] introduced variance formula that has within- and between-imputation
variability. To mimic his approach, define W and B to be the average “within-randomization”
and “between-randomization” covariances of µˆ
AR(m)
jk , that is,
W =
1
M
M∑
m=1
Vˆ
AR(m)
jk (3.3)
and
B =
1
(M − 1)
M∑
m=1
(µˆ
AR(m)
jk − µˆSMARTjk )2, (3.4)
where Vˆ
AR(m)
jk is the estimated variance for µˆ
AR(m)
jk for the m
th artificial randomization. The
estimated variance of µˆSMARTjk is then given by,
T = W +
(
M + 1
M
)
B. (3.5)
To summarize the steps, we create M data sets from M artificial randomizations. The
M data sets are analyzed using standard procedures to compute the means and then re-
sults from M analyses are combined to obtain a single estimator given in Equation 3.2.
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Equation (3.1) gives an estimate of µjk based on single artificial randomization, which is
equivalent to a “single imputation” technique that does not take into account variability
between “imputations” (or randomizations in our case) (Schafer, 1999) [34]. To make up
for the disadvantages associated with single imputation (such as underestimated standard
errors), multiple imputation technique has been suggested (Rubin, 1977, 1987) [31, 32]. The
proposed SMART estimator is mechanistically equivalent to multiple imputation technique.
SMART would account for both within and between-randomization variance.
This estimator enables us to apply tests such as the F-test and the t-test that are in-
convenient or even impossible to be applied when observations are not independent. Large
sample properties of SMART are compared with the four existing estimators using simula-
tion. Below is a formula for the variance of artificial estimator which is derived in Section 4.1.
var
(
µˆARjk
)
=
1
nQkκj
[
pij{σ2Aj + (µjk − µAj)2 − σ2AjBk − (µjk − µAjBk)2}
]
+
1
nQkκj
[
σ2AjBk + (µjk − µAjBk)2
]
.
(3.6)
The asymptotic variance of µˆARjk can be estimated either by the empirical estimator (Sec-
tion 4.2), or the model-based estimator which is obtained by substituting estimated quanti-
ties κˆj, Qˆk, pˆij, σˆ
2
Aj
, µˆAj , σˆ
2
AjBk
, µˆAjBk , µˆjk into Equation(3.6). It is similarly computed for all
other estimators. Section 4.1 refers to the variance formulas of estimators and Section 4.2
refers to their robust variance estimates.
3.2.2 IPW-BASED ESTIMATORS
We compare our SMART estimator to other competing estimators such as those based on
inverse probability weighting. To motivate the inverse probability weighting, suppose we are
interested in estimating µ11, mean outcome for strategy A1B1. Imagine that everyone in the
sample follows the regime A1B1 in Design 2 (Figure 3, page 12). In such a case, we would
estimate the mean, µ11, using the sample average. However, as in all SMAR designs, in our
sample patients receive treatment sequence other than A1B1 (those who received B2 or the
non-responders to A1 who are randomized to B2) which makes sample average estimation
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biased. To correct this bias, each subject following A1B1 is weighted by the reciprocal of the
probability of receiving treatment B1 (i.e., Q1) to account for the “missing” or unaccounted
individuals who received B2. To elaborate, a non-responder who received B1 could have
equally likely received B2. Thus, those who received B1 would be weighed by 1/Q1 because
they represent those who were randomized to B2. To estimate the A1B1 adaptive treatment
strategy, we consider outcomes of subjects consistent with following that treatment path.
The inverse probability weighted estimator (IPW) of µjk is given by,
µˆIPWjk =
1
n
n∑
i=1
WjkiYi, (3.7)
where Wjki =
Xji
κj
{
Ri +
(1−Ri)Zki
Qk
}
and κj is the probability assignment to first-stage treat-
ments Aj, j = 1, 2. The corresponding asymptotic variance for this estimator is,
var (µˆjk) =
1
n
[
1
κj
{
pij
Qk
(σ2Aj + µ
2
Aj
) + (1− pij)(σ2AjBk + µ2AjBk)
}
− µ2jk
]
. (3.8)
The model-based variance estimate is obtained by substituting κˆj, Qˆk, pˆij, σˆ
2
Aj
, µˆAj , σˆ
2
AjBk
, µˆAjBk , µˆjk
into Equation 3.8. Another variance estimate can be the so-called sandwich estimator (see
Section 4.2).
A variation of the IPW is its normalized version. As shown in [11], the normalized
inverse probability weighted (NIPW) is shown to have generally smaller variance than its
counterpart IPW. The NIPW estimator is given by,
µˆNIPWjk =
∑n
i=1WjkiYi∑n
i=1 Wjki
. (3.9)
The variance of NIPW is given by,
var(µˆjk) =
1
n
[
pij
κj
{
σ2Aj + (µjk − µAj)2
}
+
(1− pij)
κjQk
{
σ2AjBk + (µjk − µAjBk)2
}]
. (3.10)
The model-based variance estimate is obtained by substituting estimated quantities κˆj, Qˆk, pˆij, σˆ
2
Aj
,
µˆAj , σˆ
2
AjBk
, µˆAjBk , µˆjk into Equation (3.10). The robust variance estimator is given in Sec-
tion 4.2.
In the above IPW and NIPW estimators, the randomization probabilities are assumed to
be known. But, one may wish to estimate them from the data. Therefore, below we present
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another version of IPW and NIPW estimators (denoted as IPW1 and NIPW1, respectively)
that estimates κj and Qk’s from the data:
µˆIPW1jk =
1
n
n∑
i=1
WˆjkiYi (3.11)
and
µˆNIPW1jk =
∑n
i=1 WˆjkiYi∑n
i=1 Wˆjki
, (3.12)
where Wˆjki =
Xji
κˆj
{
Ri +
(1−Ri)Zki
Qˆk
}
, κˆj =
n∑n
i=1Xji
, Qˆk =
∑n
i=1Xji(1−Ri)Zki∑n
i=1Xji(1−Ri) . Details of variance
formulas and their robust estimates are shown in Sections 4.1 and 4.2. In the next subsection
we present the results from a simulation study to see how SMART estimator compare to
these existing estimators.
3.3 SIMULATION STUDY
We conducted a simulation study to evaluate the large sample properties of SMART estima-
tor with moderate sample sizes (150 and 300) and compare its performance with IPW-based
estimators. For each individual in the population, a hypothetical design similar to Design 3
on page 12 assumes that subgroup populations Yi(Aj) and Yi(AjBk) come from a normal
distribution with subgroup means: µAj = µAjB2 = 15, µAjB1 = 20, µAjB2 = 22; subgroup
variances: σ2Aj = 2
2, σ2AjBk = 8
2, for j, k = 1, 2. The initial treatment indicator Xi is gener-
ated from a binomial distribution with probability 0.5 of randomization to either A1 or A2.
The response indicator Ri is drawn from a Bernoulli distribution with probability of success
pi1 for initial treatment A1 and pi2 for A2. Randomization indicator Zi for non-responders
is generated from Bernoulli distribution with probability Q1. By definition, the outcome
Yi under strategy AjBk should follow a normal distribution since Yi(Aj) and Yi(AjBk) are
generated from a normal distribution. We considered many simulation scenarios for various
sample sizes and population parameters such as µAj , µAjBk , σ
2
Aj
, σ2AjBk , pi1, pi2, and Qk. The
true strategy means are computed using the formula µjk = pijµAj + (1− pij)µAjBk .
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We generated 10000 samples from the above population to compare the competing esti-
mators. To evaluate the performance of the estimators we calculate Monte Carlo (MCSE),
relative bias (RB, %), model-based (MBSE), robust (RSE) standard errors and coverage
probability (CP) of 95% Wald confidence intervals. These quantities are arranged as columns
in Tables 9 and 10. The rows correspond to strategy estimators. Specifically, there are four
strategies: A1B1, A1B2, A2B1 and A2B2.
Theoretically, we expect SMART estimators to be less efficient than NIPW as it uses less
number of non-responders. We provide simulation evidence summarizing this fact. SMART
are consistent estimators which makes them desirable in their application in regression based
adaptive strategy comparison (Section 3.4). The main results of the simulation are presented
in Tables 9 and 10, where the ratio of subgroup variance is held
σ2Aj
σ2AjBk
= 2
2
82
for a given sample
size (n=150, n=300). We present mean and standard error estimates for SMART when M=1
(SMART1) and M=5 (SMART5) based on Equation (3.5). The table rows are estimators
SMART1, SMART5, IPW, IPW1, NIPW, NIPW1. The first thing to note in both tables
is that the new estimator is approximately unbiased. Absolute relative biases (RB) were
less than 0.087% for both SMART1 and SMART5. Both MBSE and RSE are close to the
MCSE for SMART1 and SMART5. SMART5 has slightly higher MBSE than SMART1.
As anticipated, the variance for SMART1 is slightly smaller, as the between imputation
variance (B) is zero. They both approximately guarantee 95% CP. In Table 9 RSE and
MCSE comparison indicates that SMART1 attains very close estimates to SMART5.
In addition to SMART1 and SMART5, Table 9 provides four estimators produce unbiased
estimators of strategy means: µ11, µ12, µ21, µ22. Since it is shown that the IPW has greater
estimated strategy mean variance than its normalized version [11], we will focus on the
comparison of SMART estimators with the normalized versions of IPW across the MBSE,
RSE and MCSE. The IPW-based estimators are approximately unbiased with relative biases
less than 0.2% for IPW, less than 0.071% for IPW1, less than 0.3% for NIPW and less than
0.071% for NIPW1. Comparing columns MBSE, RSE and MCSE for SMART1 and SMART5
against the other estimators show a slightly higher standard error and hence are less efficient.
However, quite surprisingly, the IPW1 is almost equally efficient as the normalized versions
(NIPW and NIPW1).
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The agreement between the asymptotic standard errors and Monte Carlo standard error
suggests accuracy of the variance formulas of the estimators.
For the most part, all the estimators achieved coverage probabilities close to the nominal
95%. One can note, the NIPW and NIPW1 provided lower coverage probabilities of 90%
and 90%, respectively, for strategy A2B1. This calls for more examination of this strategy.
Table 10 shows simulation results when the sample size is increased to 300. Expectedly,
the standard errors of the estimators decreased. For the SMART estimator, the conclusions
were analogous to results in Table 9. In the same vein, comparisons across estimators are
consistent with results in Table 9. Due to equal response rates, pij’s, Tables 9 and 10 show
that estimated means and standard errors are nearly the same for strategies AjB1, j = 1, 2.
Common in both tables is that IPW estimator strategies A1B1 and A2B1 display higher
standard errors across columns MBSE, RSE and MCSE.
3.4 ARTIFICIAL RANDOMIZATION AND REGRESSION
It might seem that the proposed SMART approach to estimating the strategy means from
SMART designs is somewhat against the principle of sequential randomization. While this
provides approximately unbiased estimates, they are not more efficient than NIPW esti-
mators. This is expected, as the SMART approach uses less observations (e.g., half of the
responders) than NIPW. However, the utility of SMART approach is in its simplicity to allow
users to estimate/test strategy effects adjusting for other covariates. To show this, consider
that in a population where patients follow particular treatment strategies, the mean response
is modeled by
Yi = β0 +
∑
j,k=1,2
βjkSjki + γ
TVi +
∑
j,k=1,2
αTjkViSjki + i, (3.13)
with E(i) = 0, where parameters βjk, γ and αjk represent vector of coefficients for strategies
Sjk, covariates V and their interaction S ∗ V . Sjk is defined as Sjk = 1 if patient i follows
strategy AjBk, 0, otherwise.
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Table 9: Simulation results of estimators based on 10000 Monte Carlo (MC)
samples of size 150.
Estimator EST RB MBSE RSE MCSE CP
SMART1 15.01 -0.087 1.27 1.25 1.30 0.93
20.01 -0.035 0.96 0.95 0.97 0.94
14.99 0.027 1.27 1.25 1.34 0.92
20.02 -0.075 0.96 0.95 0.97 0.94
SMART5 15.01 -0.087 1.39 1.36 1.23 0.96
20.01 -0.045 0.98 0.97 0.94 0.96
15.02 -0.15 1.39 1.36 1.30 0.94
19.99 0.025 0.98 0.97 0.96 0.95
IPW 15.03 -0.20 1.85 1.83 1.86 0.93
19.99 0.067 2.52 2.47 2.61 0.93
14.97 0.18 1.86 1.83 1.92 0.93
19.99 0.032 2.53 2.47 2.66 0.93
IPW1 15.01 -0.051 1.16 1.10 1.11 0.94
19.99 0.071 0.94 0.94 0.95 0.93
14.99 0.03 1.15 1.10 1.19 0.93
19.99 0.04 0.95 0.94 0.97 0.92
NIPW 15.01 -0.29 1.16 1.16 1.19 0.92
19.99 0.074 0.92 0.92 0.93 0.93
14.99 -0.30 1.17 1.16 1.26 0.90
19.99 0.038 0.93 0.93 0.94 0.93
NIPW1 15.00 -0.051 1.18 1.10 1.12 0.92
19.99 0.071 0.94 0.94 0.95 0.93
15.00 0.026 1.18 1.10 1.19 0.90
19.99 0.041 0.94 0.94 0.97 0.93
Monte Carlo mean estimates (EST), relative bias (RB, %), Monte Carlo standard errors
(MCSE), model-based standard errors (MBSE), robust standard errors (RSE) and 95% cov-
erage probabilities (CP). CP is computed based on robust variance estimates. True strategy
means: µ11 = µ21 = 15, µ12 = µ22 = 20.
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Table 10: Simulation results of estimators based on 10000 Monte Carlo (MC)
samples of size 300.
Estimator EST RB MBSE RSE MCSE CP
SMART1 14.99 0.067 0.89 0.88 0.91 0.94
20.01 -0.05 0.68 0.67 0.67 0.95
14.99 0.067 0.89 0.88 0.96 0.92
20.02 -0.10 0.68 0.67 0.67 0.95
SMART5 15.02 -0.13 0.97 0.88 0.92 0.93
20.02 -0.085 0.69 0.67 0.68 0.94
14.99 0.01 0.97 0.88 0.97 0.92
20.01 -0.045 0.69 0.67 0.67 0.95
IPW 14.99 0.015 1.31 1.30 1.33 0.94
20.01 -0.097 1.78 1.76 1.87 0.93
14.99 0.01 1.31 1.30 1.34 0.94
20.01 -0.031 1.77 1.76 1.85 0.94
IPW1 15.00 -0.061 0.86 0.78 0.78 0.94
20.01 -0.055 0.67 0.66 0.67 0.93
14.99 0.024 0.86 0.78 0.83 0.94
20.00 -0.01 0.67 0.66 0.68 0.93
NIPW 15.03 -0.23 0.83 0.83 0.84 0.93
20.01 -0.052 0.66 0.66 0.67 0.94
15.02 -0.12 0.83 0.83 0.89 0.92
20.00 -0.01 0.66 0.66 0.67 0.94
NIPW1 15.01 -0.061 0.83 0.78 0.78 0.93
20.01 -0.055 0.67 0.66 0.67 0.94
14.99 0.024 0.83 0.78 0.83 0.92
20.00 -0.01 0.67 0.66 0.68 0.94
Monte Carlo mean estimates (EST), relative bias (RB, %), Monte Carlo standard errors
(MCSE), model-based standard errors (MBSE), robust standard errors (RSE) and 95% cov-
erage probabilities (CP). CP is computed based on robust variance estimates. True strategy
means: µ11 = µ21 = 15, µ12 = µ22 = 20.
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This is a multiple linear regression model, and if data were available from an upfront
randomization design (Ko and Wahed, 2012) [11], the parameters could be estimated using
regular regression analysis. As explained in the previous section, due to the non-separability
of the strategy indicators (a given observation can be associated to more than one strategy)
such an analysis is not feasible for SMAR designs. But note that artificial randomization
allows us to fit this regression model. As defined in Section 3.2.1, in terms of our artificially
randomized data, for a subject following regime AjBk would belong to Sjki = XjiZ
∗
i .
3.5 DATA ANALYSIS OF CALGB DATA
3.5.1 SAMPLE AND MEASURES
We apply the artificial randomization method and fit the model to the CALGB data de-
scribed in Chapter 1. There were a total of 388 patients who participated in the CALGB
8923 study of which 193 were randomized to the GM-CSF arm, and 195 were randomized to
the placebo arm. Of the the GM-CSF arm, 79 were responders and of the placebo arm, 90
were responders. Out of 79 responders to GM-CSF, 37 were randomized to intensification
therapy I while 45 out of 90 placebo responders were randomized to intensification therapy I.
The rest were randomized to intensification therapy II. The artificial randomization was ap-
plied to the subset of non-responders (114 from the GM-CSF arm and 105 from the placebo
arm).
Non-responders were superficially assumed to have received either intensification therapy
I or II with probability 0.5. Accordingly, we constructed strategy indicators to be used
as independent variables in the regression model as described in Section 3.4. We used R
(version 2.15) to fit Equation 3.13 and compute the estimators in Table 11. Table 11 depicts
mean estimates of the five strategies using SMART1, SMART5 IPW, IPW1, NIPW, NIPW1
estimators. In the analyses, we considered age (mean=69.5), sex (220 males, 168 females),
and strategy indicators as covariates in the artificial regression. The main outcome is survival
time but it is treated as being continuous.
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Table 11: Estimated strategy means and robust standard errors from the analysis
of CALGB 8923 data.
Strategy SMART1 (SE) SMART5 (SE) IPW (SE) IPW1 (SE) NIPW (SE) NIPW1 (SE)
A1B1 487.16 (70.58) 468.56 (70.11) 454.0 (70.9) 478.5 (57.9) 468.5 (59.5) 478.5 (66.5)
A1B2 521.21 (75.97) 536.46 (80.74) 454.0 (70.9) 528.0 (69.0) 468.5 (59.5) 528.0 (69.0)
A2B1 660.16 (88.23) 623.52 (90.12) 623.6 (91.3) 620.4 (71.6) 620.4 (73.4) 620.4 (71.6)
A2B2 592.72 (83.68) 627.48 (99.09) 632.6 (91.3) 629.4 (79.5) 620.4 (73.4) 629.4 (79.5)
3.5.2 RESULTS
From Table 11 rows are strategies and columns are strategy mean estimators. For each
strategy the estimates are similar across each estimator. The estimated means of strategies
sharing A1 are less than the strategies sharing A2 for all estimators. Similar observations
can be made about the corresponding standard errors. The NIPW, NIPW1 and IPW1 gave
smaller estimated standard errors than SMART which was noted in the simulation stud-
ies. SMART5 and IPW have greater standard errors than other estimators. In particular,
standard error estimates for SMART5 are considerably large.
As part of the modeling strategy we identified age, sex and strategy indicators from the
CALGB data as potential predictors in our regression model. Further, we explore possible
interaction between the strategies and age and sex. Practically, we expect significant inter-
actions to generate new strategies that specify long term survival of AML patients. In more
detail, we did the following. Three interaction models were fitted. The first contained two
interactions, namely, strategy by age and strategy by sex. The second and third models have
strategy by age and strategy by sex interactions. All the interaction models were found to
be not significant. To apply our method, we decide to keep the model with strategy and
sex interaction. Had the interaction between strategy and sex were significant, we would
choose the model in Table 12 for purposes of constructing informative strategies. Except for
age (P=0.0024), strategy, sex and the interaction terms are not significant. The p-value for
the interaction between strategy and sex is 0.086. Assuming significant interaction exists
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Table 12: Parameter Estimates for Model of CALGB 8923 data.
Parameter Estimate SE Z Pr > |Z|
Intercept 1996.75 487.42 4.10 <0.001
SA1B1 25.90 146.64 0.18 0.86
SA1B2 -156.38 149.07 -1.10 0.29
SA2B1 71.50 154.77 0.46 0.64
Sex 95.74 154.75 0.62 0.54
Age -20.98 6.87 -3.05 0.0024
SA1B1*Sex -309.39 230.22 -1.34 0.18
SA1B2*Sex 281.88 221.34 1.27 0.20
SA2B1*Sex -23.34 224.15 -0.10 0.92
between sex and treatment strategies, we defined 16 new strategies to treat patients accord-
ing to their sex. One strategy could be, “If female treat with A1B1, else treat with A1B1”,
which is denoted by “fA1B1mA1B1”. Table 13 shows estimated means. Also, displayed are
robust standard errors and confidence intervals for the sixteen strategies. Figure 5 displays
the mean estimates and corresponding 95% confidence interval. Significant strategies are
either to the right or left of the mean dotted vertical line. Similar plot called forest plot is
used to display the effect of odds ratio for logistic regression results. As can be gathered
from the table and figure, Strategies “fA1B1mA1B2” and “fA1B2mA2B1” have the smallest
and highest mean and standard errors for the SMART estimators, respectively. As our sim-
ulation results would support the robust standard error estimates for SMART5 estimator is
greater than SMART1 estimator.
This chapter introduced an unbiased SMART estimator that is based on multiple impu-
tation concepts. As a consequence, it introduced the artificial randomization technique to
compare strategies from SMAR design using regression methods.
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Table 13: Analysis of CALGB 8923 data for sixteen new strategies.
Strategy SMART1 SE CI1 SMART5 SE CI5
fA1B1mA1B1 487.16 70.58 (348.82, 625.50) 487.16 70.58 (348.82, 625.50)
fA1B1mA1B2 363.18 47.65 (269.79, 456.57) 363.18 47.65 (269.79, 456.57)
fA1B1mA2B1 513.41 78.98 (358.61, 668.21) 513.41 78.98 (358.61, 668.21)
fA1B1mA2B2 468.93 73.87 (324.15, 613.72) 468.93 73.87 (324.14, 613.72)
fA1B2mA1B1 626.00 85.76 (457.91, 794.10) 626.00 190.45 (252.72, 999.28)
fA1B2mA1B2 521.21 75.97 (372.31, 670.11) 521.21 207.92 (113.69, 928.73)
fA1B2mA2B1 667.22 95.05 (480.92, 853.52) 667.22 211.00 (253.66, 1080.78)
fA1B2mA2B2 621.43 90.93 (443.21, 799.65) 621.43 207.73 (214.28, 1028.58)
fA2B1mA1B1 620.14 79.88 (463.58, 776.70) 620.14 181.40 (264.60, 975.68)
fA2B1mA1B2 516.16 68.88 (381.16, 651.16) 516.16 199.62 (124.91, 907.41)
fA2B1mA2B1 660.16 88.23 (487.23, 833.09) 660.16 200.22 (267.73, 1052.59)
fA2B1mA2B2 615.13 84.38 (449.74, 780.51) 615.13 197.95 (227.15, 1003.11)
fA2B2mA1B1 599.14 79.38 (443.56, 754.72) 599.14 158.46 (288.56, 909.72)
fA2B2mA1B2 499.26 69.24 (363.55, 634.97) 499.26 180.48 (145.52, 853.00)
fA2B2mA2B1 634.54 87.41 (463.22, 805.86) 634.54 172.20 (297.03, 972.05)
fA2B2mA2B2 592.73 83.68 (428.72, 756.74) 592.73 173.18 (253.30, 932.16)
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Means of sixteen strategies with their confidence intervals are displayed in a forest plot where
the dots are strategy mean estimates, and lines indicate ± SE.
Figure 5: SMART1.
55
4.0 VARIANCE FORMULAS OF ESTIMATORS
4.1 VARIANCE FORMULAS
M-estimation or synonymously referred to as estimating equations are empirical or quasi-
likelihood based functions. Quasi-likelihood functions depend on specified means and vari-
ance relations of each observation [1]. Thus, M-estimation derives estimators by solving
estimating equations that are not necessarily constructed from the derivative of the log-
likelihood. Huber (1964, 1967) introduced and developed the asymptotic properties of
M-estimators. The estimating equation can be written as
∑n
i=1 ψ(Yi,Θ) = 0, where the
M-estimator Θˆ satisfies the equation,
n∑
i=1
ψ(Yi, Θˆ) = 0.
The vector Yi, i = 1, ..., n are independent and may not be identically distributed, Θ is p-
dimensional parameter, and ψ is a known (p×1) influence function independent of i or n. It is
shown that Θˆ ∼ N
(
Θ, V (Θ)
n
)
as n →∞, where V (Θ) = A(Θ)−1B(Θ){A(Θ)−1}T . Formally,
assuming Y1, Y2, ..., Yn are i.i.d and follow the distribution F, model-based estimators for A
and B are given by
A(Y, Θˆ) = EF{−ψ′(Yi, Θˆ)}
and
B(Y, Θˆ) = EF{ψ(Yi, Θˆ)ψ(Yi, Θˆ)T}
respectively.
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Using averages instead of expectations, the empirical estimators for A and B are given
by
An(Y, Θˆ) =
1
n
n∑
i=1
{−ψ′(Yi, Θˆ)}
and
Bn(Y, Θˆ) =
1
n
n∑
i=1
ψ(Yi, Θˆ)ψ(Yi, Θˆ)
T
respectively.
Below we derive the asymptotic variance for the proposed and existing estimators and
in Section 4.2, we compute the empirical variance estimators.
1. Variance of IPW Estimator
Let Θ0 = (µjk) and the ψ- function ψ(Yi,Θ0) = ψ1(Yi,Θ0) = {WjkiYi − µjk}, ψ′ = −1,
ψ(Yi,Θ0)ψ
T (Yi,Θ0) = {WjkiYi − µjk}2. Then A(Θ) = E{−ψ′(Yi,Θ0)} = 1, B(Θ) =
E{ψ(Yi,Θ0)ψT (Yi,Θ0)} = E
[(
Xji
κj
{Ri + (1−Ri)ZkiQk }Yi − µjk
)2]
= E
[(
Xji
κj
{RiYi(Aj) + (1−Ri)ZkiYi(AjBk)
Qk
} − µjk
)2]
= E
[
Xji
κ2j
{RiY 2i (Aj) +
(1−Ri)ZkiY 2i (AjBk)
Q2k
}
]
−2E
[
µjk
Xji
κj
{RiYi(Aj) + (1−Ri)ZkiYi(AjBk)
Qk
}+ µ2jk
]
= E
[
Xji
κ2j
{RiY 2i (Aj) +
(1−Ri)ZkiY 2i (AjBk)
Q2k
} − µ2jk
]
= E
[
E
[
Xji
κ2j
{RiY 2i (Aj) +
(1−Ri)ZkiY 2i (AjBk)
Q2k
} − µ2jk
]
|Xji, Ri, Yi(Aj), Yi(AjBk)
]
After a few steps of iterative expectations, we obtain
B(Θ) =
1
κj
{ pij
Qk
(σ2Aj + µ
2
Aj
) + (1− pij)(σ2AjBk + µ2AjBk)} − µ2jk.
Therefore, the IPW variance estimator is
var(Θˆ) =
1
n
A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T
=
1
nκj
{ pij
Qk
(σ2Aj + µ
2
Aj
) + (1− pij)(σ2AjBk + µ2AjBk)} − µ2jk.
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2. Variance of NIPW Estimator
Let Θ0 = (µjk) and the ψ- function ψ(Yi,Θ0) = Wjki(Yi − µjk), where ψ′(Yi,Θ0) =
−Wjki, ψ(Yi,Θ0)ψT (Yi,Θ0) = {Wjki(Yi − µjk)}2. Then A(Θ) = E{−ψ′} = E{Wjki},
B(Θ) = E{ψ(Yi,Θ0)ψT (Yi,Θ0)} = E
[
Xji
κ2j
{Ri + (1−Ri)ZkiQk }2{Yi − µjk}2
]
. Let’s expand
and evaluate A(Θ) and B(Θ).
A(Θ) = E{−ψ′} = E{Wjki}
= E
[
Xji
κj
{Ri + (1−Ri)Zk
Qk
}
]
= E
[
E
[
Xji
κj
{Ri + (1−Ri)Zk
Qk
}|Xji, Ri
]]
= E
[
Xji
κj
E
[
{Ri + (1−Ri)Zk
Qk
}|Xji, Ri
]]
= E
[
Xji
κj
[Ri + (1−Ri)]
]
= E
[
Xji
κj
]
= 1.
B(Θ) = E{ψ(Yi,Θ0)ψT (Yi,Θ0)}
= E
[
Xji
κ2j
{
Ri +
(1−Ri)Zki
Qk
}2
{Yi − µjk}2
]
= E
[
E
[
Xji
κ2j
{
Ri +
(1−Ri)Zki
Qk
}2
{RiYi(Aj) + (1−Ri)Yi(AjBk)− µjk}2
]
|Ri, Yi(Aj), Yi(AjBk)
]
= E
[
E
[
XjiRi
κ2j
[
RiY
2
i (Aj)− 2RiµjkYi(Aj) + µ2jk
]] |Ri, Yi(Aj), Yi(AjBk)]
+E
[
E
[
Xji(1−Ri)Zki
κ2jQ
2
k
[
(1−Ri)Y 2i (AjBk)
]] |Ri, Yi(Aj), Yi(AjBk)]
−E
[
E
[
Xji(1−Ri)Zki
κ2jQ
2
k
[
2(1−Ri)µjkYi(AjBk) + µ2jk
]] |Ri, Yi(Aj), Yi(AjBk)]
= E
[
E
[
Xji
κ2j
{
Ri
[
Y 2i (Aj)− 2µjkYi(Aj) + µ2jk
]}] |Ri, Yi(Aj), Yi(AjBk)]
+E [Zki|Xji, Ri, Y (Aj), Y (AjBk)]
E
[
E
[
Xji
κ2j
{
(1−Ri)
Q2k
[
Y 2i (AjBk)− 2µjkYi(AjBk) + µ2jk
]}] |Ri, Yi(Aj), Yi(AjBk)]
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Taking the expected values and rearranging the terms leads to
=
pij
κj
[
σ2Aj + (µjk − µAj)2
]
+
(1− pij)
κjQk
[
σ2AjBk + (µjk − µAjBk)2
]
.
Therefore, the NIPW variance estimator is
var(Θˆ) =
1
n
A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T
=
pij
nκj
[
σ2Aj + (µjk − µAj)2
]
+
(1− pij)
nκjQk
[
σ2AjBk + (µjk − µAjBk)2
]
.
3. Variance of AR Estimator
Let Θ0 = (µjk) and the ψ- function ψ(Yi,Θ0) = Wjki(Yi−µjk), where ψ′(Yi,Θ0) = −Wjki,
ψ(Yi,Θ0)ψ
T (Yi,Θ0) = {Wjki(Yi − µjk)}2. Then A(Θ) = E{−ψ′} = E{Wjki}, B(Θ) =
E{ψ(Yi,Θ0)ψT (Yi,Θ0)} = E
[
Xji {RiZ∗ki + (1−Ri)Zki}2 {Yi − µjk}2
]
. Let’s expand and
evaluate A(Θ) and B(Θ).
A(Θ) = E{−ψ′} = E{Wjki}
= E [Xji {RiZ∗ki + (1−Ri)Zki}]
= E [E(Xji {RiZ∗ki + (1−Ri)Zki} |Xji, Ri)]
= E [Xji {RiPki + (1−Ri)Pki}]
= E [XjiPki] = κjQk.
B(Θ) = E{ψ(Yi,Θ0)ψT (Yi,Θ0)}
= E
[
Xji {RiZ∗ki + (1−Ri)Zki}2 {Yi − µjk}2
]
= E
[
E
[
Xji {RiZ∗ki + (1−Ri)Zki}2 {RiYi(Aj) + (1−Ri)Yi(AjBk)− µjk}2
]
|Ri, Yi(Aj), Yi(AjBk)
]
= E
[
E
[
XjiRiZ
∗
ki
[
RiY
2
i (Aj)− 2RiµjkYi(Aj) + µ2jk
]] |Ri, Yi(Aj), Yi(AjBk)]
+E
[
E
[
Xji(1−Ri)Zki
[
(1−Ri)Y 2i (AjBk)− 2(1−Ri)µjkYi(AjBk) + µ2jk
]] |Ri, Yi(Aj), Yi(AjBk)]
= E
[
E
[
XjiRi
(
Y 2i (Aj)− 2µjkYi(Aj) + µ2jk
) |Xji, Ri, Yi(Aj), Yi(AjBk)]]
E [Z∗ki|Xji, Ri, Yi(Aj), Yi(AjBk)]
+E
[
E
[
Xji(1−Ri)
[
(1−Ri)Y 2i (AjBk)− 2(1−Ri)µjkYi(AjBk) + µ2jk
] |Xji, Ri, Yi(Aj), Yi(AjBk)]]
E [Zki|Xji, Ri, Yi(Aj), Yi(AjBk)]
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Taking the expected values and rearranging the terms leads to,
= Qkκjpij
[
σ2Aj + (µjk − µAj)2 − σ2AjBk − (µjk − µAjBk)2
]
+Qkκj
[
σ2AjBk + (µjk − µAjBk)2
]
.
Therefore, variance of AR estimator is
var(Θˆ) =
1
n
A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T
=
1
nQkκj
[
pij{σ2Aj + (µjk − µAj)2 − σ2AjBk − (µjk − µAjBk)2}
]
+
1
nQkκj
[
σ2AjBk + (µjk − µAjBk)2
]
.
4. Variance of NIPW1 Estimator
Let Θ0 = (κj, Qk, µjk) and ψ- function
ψ(Yi,Θ0) =

Xji − κj
Xji(1−Ri)(Zki −Qk)
Xji
κj
[
Ri +
(1−Ri)Zki
Qk
]
{Yi − µjk}
 ,
where
−ψ′(Yi,Θ0) =

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zk
Qk
]
{Yi − µjk} Xjiκj
[
(1−Ri)Zk
Q2k
]
{Yi − µjk} Xjiκj
[
Ri +
(1−Ri)Zk
Qk
]
 .
Then
A(Θ) = E{−ψ(Yi,Θ0)}
= E

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zki
Qk
]
{Yi − µjk} Xjiκj
[
(1−Ri)Zki
Q2k
]
{Yi − µjk} Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
 ,
where
i. E{Xji(1 − Ri)} = E [E{Xji(1−Ri)}|Xji] = E [XjiE{(1−Ri)}|Xji] = E{Xji(1 −
pij)} = κj(1− pij).
ii. E
Xji
κ2j
[
Ri +
(1−Ri)Zki
Qk
]
{Yi − µjk} = 0, since E(Yi) = µjk.
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iii.
Xji
κj
[
RiZki
P 2k
]
{Yi − µjk} = 0, since E(Yi) = µjk.
iv. E
[
Xji
κj
{Ri + (1−Ri)ZkiQk }
]
= E
[
E
Xji
κj
{Ri + (1−Ri)Zki
Qk
}|Xji, Ri
]
= E
[
E
Xji
κj
{Ri + (1−Ri)Zki
Qk
}|Xji, Ri
]
= E
[
Xji
κj
E{Ri + (1−Ri)}|Xji
]
= E
[
Xji
κj
]
= 1.
B(Θ) = E{ψψT}
= E

B11 B12 B13
B21 B22 B23
B31 B32 B33
 ,
where
i. B11 = E(Xji − κj)2 = var(Xji) = κj(1− κj).
ii. B12 = B21 = E{(Xji − κj)Xji(1−Ri)(Zk −Qk)} = 0.
iii. B13 = B31 = E
[
(Xji − κj)Xjiκj {Ri +
(1−Ri)Zk
Qk
}(Yi − µjk)
]
= 0, since EYi = µjk.
iv. B22 = E{Xj(1−Ri)(Zk −Qk)2}
= E
[{Xji(1−Ri)Zki −Xji(1−Ri)Qk}2]
= E
[
Xj(1−Ri)Zk +Xji(1−Ri)Q2k − 2Xji(1−Ri)Qk
]
= E
[
E
[
Xji(1−Ri)Zk +Xji(1−Ri)Q2k − 2Xji(1−Ri)Qk
] |Xji, Ri]
= E
[
E
[
Xji(1−Ri)Qk +Xji(1−Ri)Q2k − 2Xji(1−Ri)Qk
] |Xji, Ri]
= E
[
E
[
Xji(1−Ri)Q2k −Xji(1−Ri)Q2k
] |Xji, Ri]
= E
[
XjiE
[
(Q2k −Qk)Xji(1− pij)
] |Xji]
= κj(1− pij)(Q2k −Qk).
v. B23 = B32 = E
[
Xji(1−Ri)(Zki −Qk)Xjiκj {Ri +
(1−Ri)Zki
Qk
}(Yi − µjk)
]
= 0, since
EYi = µjk.
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vi. B33 = E
[
Xji
κj
{Ri + (1−Ri)ZkQk }(Yi − µjk)
]2
.
=
pij
κj
[
σ2Aj + (µjk − µAj)2
]
+
(1− pij)
κjQk
[
σ2AjBk + (µjk − µAjBk)2
]
,
which is derived above for NIPW estimator.
The variance of NIPW1 estimator is the (3, 3) entry of the matrix 1
n
{A−1(Θ)B(Θ){A−1(Θ)}T}.
5. Variance of IPW1 Estimator
Let Θ0 = (κj, Qk, µjk) and the ψ- function
ψ(Yi,Θ0) =

Xji − κj
Xji(1−Ri)(Zk −Qk)
Xji
κj
[
Ri +
(1−Ri)Zk
Qk
]
Yi − µjk
 ,
where
−ψ′(Yi,Θ0) =

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zk
Qk
]
Yi
Xji
κj
[
(1−Ri)Zk
Q2k
]
Yi 1
 .
Then A(Θ) = E{−ψ(Yi,Θ0)}
= E

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zki
Qk
]
Yi
Xji
κj
[
(1−Ri)Zk
Q2k
]
Yi 1
 ,
where
i. E{Xji(1 − Ri)} = E [E{Xji(1−Ri)}|Xji] = E [XjiE{(1−Ri)}|Xji] = E{Xji(1 −
pij)} = κj(1− pij).
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ii. E
{
Xji
κ2j
[
Ri +
(1−Ri)Zk
Qk
]
Yi
}
= E
[
E
Xji
κ2j
[
Ri +
(1−Ri)Zk
Qk
]
Yi|Xji, Ri, Yi(Aj), Yi(AjBk)
]
= E
Xji
κ2j
[
E
[
RiYi(Aj) +
(1−Ri)ZkYi(AjBk)
Qk
]
Yi|Xji, Ri, Yi(Aj), Yi(AjBk)
]
= E
Xji
κ2j
[E [RiYi(Aj) + (1−Ri)Yi(AjBk)] |Xji, Yi(Aj), Yi(AjBk)]
= E
Xji
κ2j
[E [pijYi(Aj) + (1− pij)Yi(AjBk)] |Xji, Yi(Aj), Yi(AjBk)]
= E
Xji
κ2j
[
E
[
pijµAj + (1− pij)µAjBk
] |Xji]
=
1
κj
[
pijµAj + (1− pij)µAjBk
]
=
1
κj
µjk.
iii. E
{
Xji
κj
[
(1−Ri)Zk
Q2k
]
Yi
}
= E
[
E
{
Xji
κj
[
(1−Ri)Zk
Q2k
]
Yi|Xji, Ri
}]
= E
{
Xji
κj
E
[
(1−Ri)Zk
Q2k
]
|Xji, Ri
}
E {E [Yi|Ri]}
= E
{
Xji
κj
E
[
(1−Ri)
Qk
]
|Xji
}
µjk
= E
{
Xji
κj
(1− pij)
Qk
}
µjk
=
(1− pij)
Qk
µjk.
B(Θ) = E{ψψT}
= E

B11 B12 B13
B21 B22 B23
B31 B32 B33
 ,
where
i. B11 = E(Xji − κj)2 = var(Xji) = κj(1− κj).
ii. B12 = B21 = E{(Xji − κj)Xji(1−Ri)(Zk −Qk)} = 0.
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iii. B13 = B31 = E(Xji − κj)
[
Xji
κj
[
Ri +
(1−Ri)Zki
Qk
]
Yi − µjk
]
= E
[
(Xji − κj)Xji
κj
E
[
{RiYi(Aj) + (1−Ri)ZkYi(AjBk)
Qk
} − µjk
]
|Xji, Ri, Yi(Aj), Yi(AjBk)
]
= E
[
(Xji − κj)Xji
κj
E [{RiYi(Aj) + (1−Ri)Yi(AjBk)} − µjk] |Xji, Yi(Aj), Yi(AjBk)
]
= E
[
(Xji − κj)Xji
κj
µjk − µjk
]
=
µjk
κj
E
[
(Xji − κj)2
]
=
µjk
κj
κj(1− κj) = (1− κj)µjk.
iv. B22 = E{Xi(1−Ri)(Zki −Qk)2} = κj(1− pij)(Q2k −Qk), which is the same as entry
B22 for NIPW.
v. B23 = B32 = E
{
Xji(1−Ri)(Zki −Qk){Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
Yi − µjk}
}
= 0.
vi. B33 = E
[
Xji
κj
{
Ri +
(1−Ri)Zki
Qk
}
Yi − µjk
]2
=
1
κj
{ pij
Qk
(σ2Aj + µ
2
Aj
) + (1− pij)(σ2AjBk + µ2AjBk)} − µ2jk,
which is computed for IPW above.
The variance of NIPW1 estimator is the (3, 3) entry of the matrix, 1
n
{A−1(Θ)B(Θ){A−1(Θ)}T},
4.2 VARIANCE ESTIMATORS
1. IPW Robust Variance Estimator
µˆIPWjk =
1
n
n∑
i=1
Xji
κj
{Ri + 1−Ri
Qk
Zki}Yi
=
1
n
n∑
i=1
WjkiYi
where Wjki =
Xji
κj
{Ri + 1−RiQk Zki}.
Let the ψ function for Θˆ = µˆAjBk be ψ = {WjkiYi−µjk}; ψ′ = −1, ψψT = {WjkiYi−µjk}2,
A(Θ) = 1
n
∑n
i=1−ψ
′
= 1, B(Θ) = 1
n
∑n
i=1 ψψ
T = 1
n
∑n
i=1{WjkiYi − µjk}2,
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v̂ar(Θˆ) is computed as follows
=
1
n
{A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T}
=
1
n
{ 1
n
n∑
i=1
{WjkiYi − µˆjk}2}
=
1
n2
{
n∑
i=1
{WjkiYi − µˆjk}2}.
2. NIPW Robust Variance Estimator
µˆNIPWAjBk =
∑n
i=1
Xji
κj
{Ri + 1−RiQk Zki}Yi∑n
i=1
Xji
κj
{Ri + 1−RiQk Zki}
=
∑n
i=1WjkiYi∑n
i=1Wjki
where Wjki =
Xji
κj
{Ri + 1−RiQk Zki}.
Let the ψ function for Θˆ = µˆAjBk be ψ = Wjki(Yi−µjk); ψ′ = −Wjki, ψψT = {Wjki(Yi−
µjk)}2, A(Θ) = 1n
∑n
i=1−ψ
′
= 1
n
∑n
i=1 Wjki, B(Θ) =
1
n
∑n
i=1 ψψ
T = 1
n
∑n
i=1{Wjki(Yi −
µjk)}2,
v̂ar(Θˆ) is computed as follows,
=
1
n
{A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T}
=
n∑n
i=1 Wjki
{ 1
n2
n∑
i=1
{Wjki(Yi − µˆjk)}2} n∑n
i=1 Wjki
=
∑n
i=1{Wjki(Yi − µˆjk)}2}
(
∑n
i=1Wjki)
2
3. AR Robust Variance Estimator
The artificial randomized (AR) estimators is given by,
µˆSMARTjk =
∑n
i=1Xji {RiZ∗ki + (1−Ri)Zki}Yi∑n
i=1Xji {RiZ∗ki + (1−Ri)Zki}
=
∑n
i=1WjkiYi∑n
i=1Wjki
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where Wjki = Xji {RiZ∗ki + (1−Ri)Zki}.
Let the ψ function for Θˆ = µˆAjBk be ψ = Wjki(Yi−µjk), ψ′ = −Wjki, ψψT = {Wjki(Yi−
µjk)}2, A(Θ) = 1n
∑n
i=1−ψ
′
= 1
n
∑n
i=1 Wjki, B(Θ) =
1
n
∑n
i=1 ψψ
T = 1
n
∑n
i=1{Wjki(Yi −
µjk)}2,
v̂ar(Θˆ) is computed as follows
=
1
n
var(Θˆ)
=
1
n
{A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T}
=
n∑n
i=1 Wjki
{ 1
n2
n∑
i=1
{Wjki(Yi − µjk)}2} n∑n
i=1 Wjki
=
∑n
i=1{Wjki(Yi − µjk)}2}
(
∑n
i=1Wjki)
2
4. NIPW1 Robust Variance Estimator
µˆNIPWAjBk =
∑n
i=1
Xji
κj
{Ri + 1−RiQk Zki}Yi∑n
i=1
Xji
κj
{Ri + 1−RiQk Zki}
=
∑n
i=1WjkiYi∑n
i=1Wjki
where Wjki =
Xji
κj
{Ri + 1−RiQk Zki}.
Let the ψ-function for Θ = (κj, Qk, µjk) be
ψ(Θ, Yi) =

Xji − κj
Xji(1−Ri)(Zki −Qk)
Xji
κj
[
Ri +
(1−Ri)Zki
Qk
]
{Yi − µjk}
 ,
−ψ′(Yi,Θ0) =

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zki
Qk
]
{Yi − µjk} Xjiκj
[
(1−Ri)Zki
Q2k
]
{Yi − µjk} Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
 ,
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A(Θ) = 1
n
∑n
i=1−ψ(Θ, Yi)
=
n∑
i=1

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zki
Qk
]
{Yi − µjk} Xjiκj
[
(1−Ri)Zki
Q2k
]
{Yi − µjk} Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
 .
B(Θ) = 1
n
∑n
i=1 ψψ
T
=
n∑
i=1

B11 B12 B13
B21 B22 B23
B31 B32 B33
 ,
where
i. B11 =
∑n
i=1(Xji − κj)2.
ii. B12 = B21 =
∑n
i=1(Xji − κj)Xji(1−Ri)(Zki −Qk).
iii. B13 = B31 =
∑n
i=1(Xji − κj)Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
(Yi − µjk).
iv. B22 =
∑n
i=1Xi(1−Ri)(Zki −Qk)2.
v. B23 = B32 =
∑n
i=1Xji(1−Ri)(Zki −Qk)Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
(Yi − µjk).
vi. B33 =
∑n
i=1
[
Xji
κj
[
Ri +
(1−Ri)Zki
Qk
]
(Yi − µjk)
]2
.
The robust variance estimator of the variance of NIPW1 estimator is the (3, 3) entry of
matrix 1
n
{A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T}.
5. IPW1 Robust Variance Estimator
µˆIPWjk =
1
n
n∑
i=1
Xji
κj
{Ri + 1−Ri
Qk
Zki}Yi
=
1
n
n∑
i=1
WjkiYi
where Wjki =
Xji
κj
{Ri + 1−RiQk Zki}.
Let the ψ-function for Θ = (κj, Qk, µjk) be
ψ(Θ, Yi) =

Xji − κj
Xji(1−Ri)(Zki −Qk)
Xji
κj
[
Ri +
(1−Ri)Zki
Qk
]
Yi − µjk
 ,
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−ψ′(Yi,Θ0) =

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zki
Qk
]
Yi
Xji
κj
[
(1−Ri)Zki
Q2k
]
Yi 1
 ,
A(Θ) = 1
n
∑n
i=1−ψ(Θ, Yi)
=
n∑
i=1

1 0 0
0 Xji(1−Ri) 0
Xji
κ2j
[
Ri +
(1−Ri)Zki
Qk
]
Yi
Xji
κj
[
(1−Ri)Zki
Q2k
]
Yi 1
 .
B(Θ) = 1
n
∑n
i=1 ψψ
T
=
n∑
i=1

B11 B12 B13
B21 B22 B23
B31 B32 B33
 ,
where
i. B11 =
∑n
i=1(Xji − κj)2.
ii. B12 = B21 =
∑n
i=1(Xji − κj)Xji(1−Ri)(Zki −Qk).
iii. B13 = B31 =
∑n
i=1(Xji − κj){Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
Yi − µjk}.
iv. B22 =
∑n
i=1Xi(1−Ri)(Zki −Qk)2.
v. B23 = B32 =
∑n
i=1Xji(1−Ri)(Zki −Qk){Xjiκj
[
Ri +
(1−Ri)Zki
Qk
]
Yi − µjk}.
vi. B33 =
∑n
i=1
[
Xji
κj
[
Ri +
(1−Ri)Zki
Qk
]
Yi − µjk
]2
.
The robust variance estimate of IPW1 is the (3, 3) entry of matrix 1
n
{A−1(Θˆ)B(Θˆ){A−1(Θˆ)}T}.
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5.0 DISCUSSION AND FUTURE WORK
Adapting or personalizing treatments due to heterogeneous response profiles is becoming
important for treating patients with chronic diseases. Routine sequential dose adjustment,
treatment choice based on history of covariates and past treatments are essential features of
adaptive treatment strategies. SMAR designs enable construction of pre-specified strategies
for future patients.
This chapter presents a synopsis of the dissertation and future work. This dissertation
makes two fundamental contributions to the literature of adaptive treatment strategies.
In Chapter 2, we introduced sample size formulas that will be useful when designing two-
stage SMAR trials. The formula is based on Wald-type test statistic. An overall sample size
formula to detect any difference among all strategy means as well as a sample size formula to
detect pairwise differences are provided. Often, the interest is to compare ATSs embedded
within SMAR designs. One approach is to conduct hypothesis testing to compare the ATS
means. This can be achieved using IPW or g-computation techniques to estimate strategy
means and compare. However, investigators are interested in using regression models to
estimate ATS means, compare among them and make pertinent inferences by allowing co-
variate adjustments. To specifically deal with this, in Chapter 3, we introduced the concept
of ‘artificial randomization’. Artificial randomization puts subjects into unique classes which
then makes regression possible. Due to its sequential nature, data from SMAR designs are
manipulated before it becomes available for regression methods. To elaborate implementa-
tion of the method we used the CALGB data to perform a data analysis. One of the key
benefits of artificial randomization is that using the initial regression results, we are able to
create more strategies that could inform disease management.
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      We have proposed an unbiased estimator called simple multiple artificial randomized tool 
(SMART) which is easier to implement. SMART specifies artificial randomization to create
M=1 to M=5 data sets to create a single estimate and standard error. It is worth investi- 
gating properties of the estimator for higher values of M by changing assumed population
parameters. Softwares such as R or SAS can be used to implement the regression as the data
that is artificially randomized becomes readily available. There is a challenge to extend the
methodology to SMAR designs with more than two stages. It could easily be adapted to
binary, survival outcomes. Our method is limited to two-stage, specific designs where either
first stage responders or non-responders do not get re-randomized.
When analyzing data from SMAR designs, it is of interest to test equality of adaptive
treatment strategies (ATSs). In the usual setting, hypothesis testing is carried out para-
metrically using test statistics developed for IPW or g-estimation. Non-parametric tests
are often attractive for small sample sizes. For future work, permutation tests could be
considered.
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